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Gonadotropin releasing hormone (GnRH) is a key reproductive hormone in vertebrates and 
exerts its effects via the GnRH receptor (GnRHR) to result in the synthesis and release of the 
gonadotropin hormones in the pituitary gonadotrope cells. GnRHR expression is likely to be 
regulated in a tissue- and cell- specific manner. A variety of hormones, including GnRH itself, 
estrogen, progesterone, inhibin, and testosterone have been shown to regulate GnRHR 
expression. Steroidogenic Factor-I (SF-I), a member of the orphan nuclear receptor 
transcription factor family, regulates the expression of both the gonadotropin hormones in the 
pituitary and the steroidogenic enzymes in the gonads and adrenal gland, and provides a 
potential molecular mechanism for coordinate control of reproductive function. SF-I binds to a 
gonadotrope-specific element (GSE) in the promoters of the gonadotropin hormones. 
Our studies involved investigating whether SF- I plays a role in tissue-specific regulation of 
GnRHR gene expression. A genomic clone of the mouse GnRHR gene contains a putative SF- I 
site at about -15 relative to the translation start site. We demonstrate the presence of a factor 
with SF-I-like DNA-binding activity in the gonadotrope cell lines, aT3-l and aT4, by gel 
retardation assays. DNasel footprinting reveals that the major DNA-binding activity in aT3-l 
cells on the GnRHR promoter occurs at the SF-I-like site. The SF-I-like sequence specificity of 
the interaction is demonstrated by gel redardation and DNasel footprinting assays using specific 
and mutated oligonucleotides as competitors. Northern blot analysis suggests that GnRHR 
expression is not solely dependent on the presence of SF-I, as aT4 cells do not express GnRHR 
but a SF-I transcript is seen in these cells. Promoter function was analysed by constructing 
plasmids containing 563 bp of the GnRHR gene 5' to the ATG translation start site linked to a 
vi 
luciferase reporter gene, followed by transfection of these constructs into different cell lines. In 
addition, a mutant construct containing a mutated SF-I site was tested. We demonstrate that 
this 563 bp of the GnRHR gene contains strong promoter activity in both pituitary gonadotrope 
(a.T3-I) and somatotrope (GH3) cells, but not in non-pituitary (COS-I) cells. Thus promoter 
activity appears to be tissue specific but not gonadotrope specific. The presence of a mutated 
SF-I site in the 563 bp GnRHR gene fragment did not significantly effect the promoter activity, 
showing that binding of SF- I protein to this site is not necessary for high levels of GnRHR 
expression in the pituitary gonadotropes. 
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CHAPTER I 
LITERATURE REVIEW 
1. Structure and function of GnRH and GnRHR 
1 
Gonadotropin releasing hormone (GnRH) is a hypothalamic decapeptide hormone, which 
controls reproductive function by stimulating the release of the gonadotropins, luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary. GnRH is 
secreted in a pulsatile manner, from the medial basal hypothalamus at intervals of 1-2 hours 
according to the species. From there it is delivered to the gonadotrophs, via the hypophysial 
portal circulation, where it binds to its receptor, the GnRH receptor (Ben-Menahem et al. 1995; 
Hazum and Conn, 1988). LH and FSH are secreted into the systemic circulation from the 
gonadotrophs in a pulsatile manner parallel to GnRH secretion. The gonadotropins in turn exert 
regulatory effects on the gonads to promote reproductive homeostasis (Hazum and Conn, 1988, 
Fig. 1.1). In addition to indirectly effecting gonadal function, GnRH has also been shown to 
have direct actions on gonads in some species by inhibiting steroidogenesis in males and 
ovulation in females (Hsueh and Jones, 1981 ). The ability of GnRH to stimulate reproductive 
function at low pulsatile doses, while suppressing them at high doses has been clinically 
exploited for various purposes including induction of ovulation and spermatogenesis, 
contraception, and for the treatment of precocious puberty, endometriosis, and steroid-
dependent tumours (i.e. prostate and breast cancer) (Ziporyn, 1985). 
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Figure 1.1. Hypothalamic-pituitary-gonadal axis. The hypothalamic peptide GnRH, is released 
in a pulsatile fashion into the hypophysial portal circulation and interacts with receptors (GnRH 
receptors) on gonadotrope cells in the pituitary (Stojilkovic et al. 1994). GnRH has been 
shown to regulate its own production in the hypothalamus. The gonadotropes secrete LH and 
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FSH, which effect steroidogenesis in the gonads. Sex steroid hormones, estrogens, 
progesterones, and testosterone have effects on LH and FSH secretion that may be mediated at 
the hypothalamus, the pituitary, or both (Gharib et al. 1990). Steroidogenic factor-I (SF-1) is 
a transcription factor which has been shown to regulate estradiol and androgens in the gonads, 
glucocorticoids and aldosterone in the adrenal gland, and both LH and FSH synthesis in the 
pituitary gland (Ingraham et al. 1994; Lala et al. 1992; Lynch et al. 1993). SF-1 may also 
regulate GnRH receptor gene expression in the pituitary gland. It is also speculated that SF-1 
may regulate the reproductive system at the level of the hypothalamus (Barnhart and Mellon, 
1994). 
1.1. Molecular structure of GnRH 
Mammalian GnRH (mGnRH) was originally isolated from pig (Matsuo et al. 1971) and sheep 
(Amoss et al. 1971) hypothalami. Mammalian GnRH is conserved in rat (Adelman et al. 1986), 
mouse (Seeburg et al. 1987), human (Adelman et al. 1986) and frog hypothalami. Two forms 
of GnRH were isolated from chicken hypothalami, namely chicken GnRH I ( cGnRH I) (King 
and Millar, 1982a and b; Miyamoto et al. 1983) and chicken GnRH II ( cGnRH II) (Miyamoto 
et al. 1984). Four GnRHs were isolated from fish hypothalami: salmon GnRH (sGnRH) 
(Sherwood et al. 1983), lamprey GnRH (lGnRH) (Sherwood et al. 1986), catfish GnRH (cf 
GnRH) (Ngamvongchon et al. 1992) and dogfish GnRH (df GnRH) (Lovejoy et al. 1992). 
Seven forms of GnRH which are highly conserved, have been identified (King and Millar, 1992, 
Fig. 1.2). 
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Figure 1.2. Primary structures of GnRHs isolated from vertebrate brain. The boxed areas show 
conserved regions (King and Millar, 1992). 
Two forms of GnRH occur within a single species, namely cGnRH I and cGnRH II (King and 
Millar, 1992). It is thought that the main role of cGnRH I, which is variable in structure, is to 
regulate pituitary gonadotropin secretion while cGnRH II which is highly conserved and is more 
prevalent in extrahypothalamic brain areas may function as a neurotransmitter or 
neuromodulator. The notion that cGnRH II may function as a neurotransmitter or 
neuromodulator is supported by several findings which are reviewed in more detail by King and 
Millar (1992). GnRH exerts its effect on reproductive function by binding to GnRH receptors 
(GnRHRs) on gonadotrope cells, to stimulate the synthesis and release of the gonadotropin 
hormones from pituitary cells. Internalisation of GnRH agonists in gonadotrophs occurs via 
receptor-mediated endocytosis (Suarez-Quian et al. 1986). After internalisation, the receptor-
ligand complex undergoes dissociation, followed by degradation of the ligand and partial 
recycling of the receptors (Schvartz and Hazum, 1987). In contrast to the rapid internalisation 
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of the GnRH agonists, GnRH antagonists remain bound to the cell surface for much longer 
(Loumaye and Catt, 1982). 
1.2. The Gonadotropin-releasing hormone receptor 
The GnRH receptor (GnRHR) is a 327 amino acid plasma membrane-associated protein and a 
member of the G-protein-coupled receptor family (Tsutsumi et al. 1992). The GnRH receptor 
has an extracellular amino terminus and seven hydrophobic membrane spanning a-helices. 
However, the GnRH receptor distinguishes itself from other G-protein coupled receptors in that 
it does not possess a cytoplasmic carboxy-terminal domain believed to be functionally important 




Figure 1.3. Structure of the mouse pituitary GnRH receptor. The seven putative 
transmembrane domains, and N-glycosylation and phosphorylation (*) sites are shown. A 
putative disulfide bond between the first and second extracellular loops is indicated by -S-S-. 
Figure taken from Stojilkovic et al. 1994. 
The GnRH receptor is a glycoprotein and binds its ligand, GnRH with a high affinity. The N-
glycosylation sites in the GnRH receptor are believed to be important for receptor expression 
and stability but not for ligand binding (Davidson et al. 1995). Six mammalian GnRH receptors 
have been cloned and characterised, including the mouse (Tsutsumi et al. 1992; Reinhart et al. 
1992), rat (Kaiser et al. 1992; Eidne et al. 1992; Perrin et al. 1993), human (Kakar et al. 1992; 
Chi et al. 1993 ), sheep (Brooks et al. 1993; Illing et al. 1993 ), cow (Kakar et al. 1993) and pig 
(Weesner and Matteri, 1994). The GnRH receptor is highly conserved amongst mammalian 
species and show more than 85% amino acid homology. The GnRH receptor is located 
primarily in the anterior pituitary gonadotrophs, where binding of the GnRH receptor to its 
ligand occurs. In addition to the gonadotrophs, GnRH receptors have been widely reported in 
the gonads, placenta, adrenal glands, the central nervous system and some neoplasmic tissues 
(Stojilkovic et al. 1994). 
1.3. Activation of GnRH receptors 
The GnRH receptor is activated when its ligand, GnRH, binds to it. A ligand receptor/G-protein 
coupled complex is formed which activates phospholipase C (Bruder et al. 1992). 
Phospholipase C cleaves phosphotidyl inositol 4,5,-biphosphate to diacylglycerol (DAG) and 
1,4,5,-triphosphate. DAG then activates protein kinase C (PKC) which then undergoes a 
translocation from the cytosol to the plasma membrane. PKC is a family of enzymes, which, 
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when activated phosphorylates many proteins and results in the induction or activation of many 
nuclear transcription factors. These transcription factors may positively or negatively regulate 
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Figure 1.4. Diagram of the second messenger system in which DAG stimulates PKC to activate 
transcriptional factors that positively or negatively regulate gene expression (Bruder et al. 
1992). 
2. Regulation of GnRH receptor gene expression in gonadotropes 
The GnRH receptor gene is likely to be regulated at several levels, for example, transcriptional, 
post transcriptional (RNA processing, RNA transport, RNA stability), translational and post 
translational modification (protein folding, transport, degradation). A major part of this 
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regulation is likely to be at the transcriptional level, as several studies have shown that changes 
in GnRH receptor number are paralleled by changes in steady state mRNA levels for the 
receptor (Albarracin et al. 1994). Kaiser et al. has shown that pulsatile application of GnRH to 
cultured rat primary pituitary cells increases receptor mRNA several-fold (1993). Multiple 
transcription start sites have been detected in the human, mouse and rat GnRH receptor genes, 
indicating that regulation of transcription may occur via start-site selection (Albarracin et al. 
1994; Fan et al. 199 5; Reinhart et al. 1997). Another level of GnRH receptor regulation may be 
via RNA processing as multiple and different RNA transcripts have been detected in expressing 
tissues (Stojilkovic et al. 1994). Since the receptor is only found in selected tissues, it is likely 
to be subjected to strict tissue-specific regulation. The GnRH receptor gene is likely to be 
regulated in an extremely interesting and complex manner, by both positive and negative cis-
regulatory transcription elements, as well as by a variety of hormones including GnRH itself, 
estrogen, progesterone, inhibin, activin A and testosterone (Clayton and Catt, 1981 ; Fernandez-
Vazquez et al. l 996;a.Laws et al. 1990; Kaiser et al. 1993; Quinones-Jenab et al. 1996; Savoy-
Moore et al. 1980). It is thought that regulation of the GnRH receptor gene is an important 
control point in the reproductive cycle, since GnRH, gonadal steroids and peptides have been 
shown to effect receptor mRN A levels (Eidne, 1994; Fernandez-Vazquez et al. 1996; 
Hamernik et al. 1995; Quinones-Jenab et al. 1996). Alarid and Mellon (1995) have shown that 
increased levels of cAMP inhibit GnRH receptor gene expression posttranscriptionally by 
destabilising mRNA. GnRH receptor gene regulation is reviewed in more detail by Leung and 
Peng (1996) and Stojilkovic et al. (1994). It is imperative to determine GnRH receptor gene 
structure, as well as identifying transcription start sites and DNA control regions in the 
promoter that may regulate GnRH receptor gene expression in order to understand the possible 
implications in control of the reproductive system. 
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2.1. GnRH receptor gene structure 
The intron-exon structure of the human (Fan et al. 1994), the mouse (Albarracin et al. 1994; 
Zhou and Sealfon, 1994) and rat (Reinhart et al. 1997) GnRH receptor genes are similar. Exon 
1 carries the 5 '-untranslated region and codes for transmembrane domains (TM) 1-111 and a 
portion of TM IV. Exon 1 is 1272 bp, 584 bp, and 625 bp long in the human (Fan et al. 1995), 
mouse (Albarracin et al. 1994; Zhou and Sealfon, 1994) and rat (Reinhart et al. 1997) GnRH 
receptor genes, respectively. Exon 2 which is 219 bp long in the human and 217 bp long in both 
the mouse and rat GnRH receptor genes codes for the remainder of TM IV as well as TM V. 
Exon 3 codes for TMs VI and VII and the COOR-terminal tail part of receptor together with 
the 3'-untranslated region and is 3300 bp, 803 bp and 1476 bp long in the human, mouse and 
rat GnRH receptor genes, respectively (Albarracin et al. 1994; Fan et al. 1995; Reinhart et al. 
1997; Zhou and Sealfon, 1994). The entire gene is over 20 kb long with the first intron being at 
least 4 kb, 15 kb and 12 kb in length in the human, mouse and rat, respectively. The second 
intron is 5 kb long in both the human and mouse, but only 2.5 kb long in the rat. The intron-
exon structure of the mouse GnRH receptor gene is depicted in Fig. 1. 5. 
5' 
5' 
TMI II Ill IV V 
3' gene structu re 
1--- -------' 3' c D N A 
VI VII 
l,__J 
0 . 1kb 
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Figure 1.5. Intron-exon structure of the mouse GnRH receptor gene and structure of mouse 
GnRH receptor cDNA. Open boxes indicates the protein coding regions and hatched boxes are 
the putative transmembrane domains (Zhou and Sealfon, 1994). 
2.2. Characterisation of the 5' end of the GnRH receptor cDNA 
Primer extension analysis detected multiple transcription initiation start sites at positions -742, -
733, -167, -144 and -43 relative to the translational start site in the human GnRH receptor gene 
(Fan et al. 1995). Major transcription start sites at -63 and -103 nucleotides relative to the start 
codon were detected in the mouse (Albarracin et al. 1994; Hapgood, unpublished data) and rat 
(Reinhart et al. 1997) GnRH receptor genes, respectively. The existence of multiple, as well as 
far upstream transcription start sites in the human GnRH receptor gene suggests the potential 
for more numerous and diverse transcription elements in the human promoter than in those of 
rodents. 
Several consensus sites for putative transcription factors have been identified, by sequence 
analysis, in the region upstream of the transcription start sites of the human, mouse and rat 
GnRH receptor genes. Whether these binding sites have functional significance needs to be 
determined. Not much has been published on establishing functional activity of promoter 
regions, but for the mouse, Albarracin et al. ( 1994) has shown that 1. 2 kb of the 5 '-flanking 
region of the GnRH receptor gene is essential for promoter function and tissue specificity. 
The TATA box, important for determining the accurate start of transcription, appears to be 
absent in the mouse 5 '-flanking region although sequence analysis of the 5' end of the human 
and rat GnRH receptor genes revealed the presence of five (-57, -154, -193-, -761, -774 
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upstream of the start codon) and one putative TATA box at position -126 relative to the 
translational start site in the human and rat genes, respectively. Several CAAT sequences are 
interspersed among the TATA boxes (Fan et al. 1995; Reinhart et al. 1997). It is unusual for G-
protein-coupled receptors to have consensus TAT A and CAA T sequences. In the absence of 
consensus TATA and CAAT sequences G-protein-coupled receptors may be regulated by 
mechanisms such as GATA motifs (Aird et al. 1994), AT-rich elements (Wobbe and Stahl, 
1990), CpG islands and transcriptional initiator elements in conjunction with Sp 1 binding sites 
(Javahery et al. 1994). The human and rat GnRH receptor genes fall into the category of 
TATA-containing G-protein-coupled receptors, but whether the absence or presence of TATA 
boxes is characteristic of this receptor family needs to be further investigated, as relatively few 
G-protein coupled receptor promoter regions have been sequenced. A putative cAMP response 
element (CRE), 5'-tgaagtct-3 ', was detected in the human GnRH receptor gene at position -
1533 to -1526 relative to the start codon and is 75% homologous to the published sequence. 
Sequence analysis further revealed the presence of a putative glucocorticoid/progesterone 
response element (GRE/PRE 5'-gttacacagtattct-3') at position -121 to -135 relative to the 
translation start site. The presence of these sequences suggests that cAMP and glucocorticoids 
or progesterone may play a role in the regulation of the human GnRH receptor gene. Consensus 
binding sites for eukaryotic transcription factors, such as GATA-1, Oct-I and engrailed protein 
was also identified. Several PEA-3 binding sites, 5 ' -aggaag-3 ', which act as a phorbol ester 
responsive element in some genes, have also been detected. The human, mouse and rat GnRHR 
genes all have a putative AP-1 site, which has been shown to confer responsiveness to protein 
kinase C, in other promoters. A Pit-I site has been detected in the human and rat GnRH 
receptor 5' -tlank (Fan et al. 1995; Reinhart et al. 1997). Pit-I is an anterior pituitary specific 
transcription factor that has been reported to be involved in the regulation of anterior pituitary 
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hormones. A possible GnRH-responsive element was found in the mouse GnRHR 5' -flanking 
region (Albarracin et al. 1994). A 30-bp DNA sequence (gonadotrope-specific element (GSE)) 
which is proposed to dictate gonadotrope-specific expression of the a-subunit of the 
glycoprotein hormones has been detected in the 5 '-flanking region of the a-subunit gene. 
Barnhart and Mellon (1994) has shown that the transcription factor, steroidogenic factor-I , 
binds to an 8-bp stretch of nucleotides within the GSE. An identical 8-bp putative GSE or SF-1-
like sequence was found in the 5'-flanking region of the mouse (Albarracin et al. 1994) and rat 
(Reinhart et al. 1997) GnRH receptor genes. Whether the SF-1-like sequence identified in the 
5' -flanking region of the mouse GnRH receptor gene plays a role in GnRHR gene regulation 
remains to be investigated. The finding that SF-1 regulates gonadotropin expression and that a 
putative SF-1 site was detected in the putative promoter region of the GnRHR gene suggests 
that SF-1 may form part of a conserved global regulatory pathway co-ordinating reproductive 
function. 
2.3. The gonadotropins 
LH and FSH are glycoprotein hormones which possess N-linked carbohydrate chains attached 
to specific asparagine residues. The type and quantity of oligosaccharide present on the 
gonadotropin effects the clearance of the hormone, their bioactivity, and how they are sorted 
intracellularly. The gonadotropins are heterodimers, composed of a common a-subunit and a 
unique {3-subunit that is responsible for the specificity of the hormone (Gharib et al. 1990). 
2.4. Gonadotropin regulation 
The amplitude and frequency of GnRH release determines the amount of gonadotropins 
secreted. Pulsatile GnRH release stimulates gonadotropin secretion, while continuous 
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administration leads to suppression of gonadotropin secretion (Kay et al. 1994). GnRH acts at 
the pituitary level via the GnRHR, which is activated when its ligand GnRH binds to it. This 
results in the activation of phospholipase C which leads to elevated levels of DAG and 
intracellular Ca2+ and results in activation of PCK (Bruder et al. 1992). Ben-Menahem et al. 
(1995) have shown that protein kinase C (PKC) and Ca2+ are involved in GnRH mediated 
stimulation of gonadotropin secretion and that cross talk exists between PKC and ca2+, which 
are involved in mediating the early and late phases of GnRH action. Sex steroids also effect 
gonadotropin secretion, however it is not sure whether regulation occurs because of alterations 
in GnRH secretion induced by the steroids at the hypothalamus or whether regulation occurs 
directly at the level of the pituitary gland, or both (Karsch, 1987; Knobil, 197 4; Schally et al. 
1972). Gonadal peptides, for example inhibins, activins and follistatin, have been identified that 
can regulate gonadotropin secretion by direct effects on the pituitary (Attardi et al. 1995; Ling 
et al. 1985; Padmanabhan et al. 1996). In addition, SF-1 has been shown to regulate the human 
and rat glycoprotein a and P-subunit genes in pituitary gonadotrophs by binding to a 
gonadotrope-specific element (GSE) in the promoter region of these genes (Barnhart and 
Mellon, 1994; Halvorsen et al. 1996a and b; Hom et al. 1992; Keri and Nilson, 1996). 
2.5. The gonadotropins and SF-1 
Tissue specific expression of the a-subunit gene is believed to be mediated by a gonadotrope-
specific element (GSE) which is conserved in all mammalian a-subunit genes thus far known 
(Barnhart and Mellon, 1994). The GSE contains the sequence 5 ' -tg( a/t )cc-3 ', which comprises 
a nuclear receptor binding half-site (Laudet et al. 1992). Variations of this sequence are also 
found in the promoter regions of many different genes which play a role in steroidogenesis, 
sexual differentiation and adult reproductive function (Barnhart and Mellon, 1994) (Fig. 1.6). 
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Using the immortalised mouse gonadotroph precursor cell line aT3-l, which expresses the a-
subunit and GnRHR but not LHP or FSHP mRNA, Barnhart and Mellon showed that SF-1 
binds to the human GSE (Windle et al. 1990; Barnhart and Mellon, 1994). They also showed 
that reporter constructs containing the a-subunit GSE are expressed at higher levels in cell lines 
with endogenous SF-1 than in cells lacking SF-1, demonstrating the potential of the GSE as an 
SF-I-dependent regulatory element. These findings supports a role for SF-1 in tissue specific 
transcriptional activation of the a-subunit gene. 
GnRHR 
SF-1 site? 
mouse !11G~C TGG 
human LJjG CC GGG 
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Figure 1.6. The GSE is homologous to the binding sites for members of the steroid receptor 
superfamily. 
In addition to regulating a-subunit gene expression, SF-1 also regulates P-subunit gene 
expression. The rat LHP gene promoter contains a consensus GSE (TGACCTTGT) at -127 to -
119 relative to the transcription start site, while the bovine LHP gene promoter contains a 
consensus GSE at -125 to -117 relative to the transcription start site. Keri and Nilson have 
shown that transfection of a T3- l cells, who endogenously express SF-1 , with an SF-1 
expression vector, increases transcription of the LHP promoter. Furthermore they have used 
transgenic mice with the wild type or mutant bovine LHP promoter to prove the physiological 
significance of the LHP SF-1 consensus sequence (1996). Co-transfection of an SF-1 containing 
expression vector and an LHP luciferase reporter construct into CV-1 cells, which lack 
endogenous SF-1 , caused a 56-fold increase in luciferase activity (Halvorson et al. 1996b). 
Taken together these results suggest that SF-1 may participate in expression of the LHP gene 
by gonadotropes. Halvorson et al. has further shown that GnRH and the PKC system interact 
with SF-1 to increase LHP activity in the rat (Halvorson et al. , 1996a). SF-1 and the estradiol 
receptor act in synergism to regulate the expression of the salmon gonadotropin IIP subunit 
gene (Drean et al. , 1996). 
2.6. Steroidogenic factor-1 (SF-1) 
Steroidogenic factor-I , a 54 kDa protein, is a member of the orphan nuclear receptor 
transcription factor superfarnily (Barnhart and Mellon, 1994). The human SF-I protein consists 
of 461 amino acids and is highly homologous to those of mammalian counterparts. The gene is 
30 kb long and contains seven exons, including a non-coding exon 1 (Oba et al. 1996). 
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Although SF-1, or sometimes called adrenal 4-binding protein ( Ad4bp ), was first described in 
the adrenal gland where it is a key regulator of steroidogenic enzymes in adrenocortical cells, it 
is also found in the testis, ovary, pituitary gonadotrope cells and embryonic ventral 
diencephalon which gives rise to part of the hypothalamus (Ikeda et al. 1993; Ikeda et al. 1994; 
Ingraham et al. 1994). 
SF-1 was first identified through its ability to bind to and co-ordinately regulate the expression 
of genes in the corticosteroid biosynthetic pathway (Lala et al. 1992). Subsequently, SF-1 was 
shown to bind to and regulate the rat cytochrome P450 aromatase gene, which catalyses the 
conversion of androgens to estrogens ( Lynch et al. 1993). Although SF-1 is predominantly 
expressed in the adrenal gland it is selectively expressed in the pituitary gonadotrope cells, 
where it is proposed to regulate the expression of many different gonadotrope specific genes 
(Barnhart and Mellon, 1994; Halvorson et al. 1996b; Keri and Nilson, 1996). The occurrence of 
SF-1 in the pituitary and hypothalamus suggests that the function of SF-1 extents well beyond 
regulating steroidogenic enzymes and that SF-1 is essential for reproductive behaviour 
(Barnhart and Mellon, 1994). This is a field of active research and knock out experiments have 
been done to determine the role of SF-1 (Ikeda et al. 1995; Ingraham et al. 1994; Luo et al. 
1994) 
2. 7. Knock out experiments 
Sequence analysis revealed that the SF-1 transcript is homologous to FTZ-Fl , a gene product 
that regulates the expression of the Drosophila fushi tarazu (ftz) homeobox gene (Lavorgna et 
al. 1991; Ueda et al. 1990). In knock out experiments with mice, Luo et al. (1994), showed 
that mice in which the Ftz-FI gene (encoding SF-1) was disrupted, lacked adrenal glands and 
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gonads and had female internal genitalia. This is consistent with the fact that SF-1 regulates the 
biosynthesis of androgens (Lynch et al. 1993) and Mullerian-inhibiting substance (Shen et al. 
1994), which are important mediators of male sexual differentiation. Studies showed that Ftz-
F I disrupted mice lacked transcripts for the gonadotrope-specific markers LHP, FSHP and the 
GnRHR and exhibited decreased expression of the a-subunit of the glycoprotein hormones 
(Ingraham et al. 1994). These findings imply that SF-1 is required for development of cells of 
the gonadotrope lineage or for expression of multiple gonadotrope-specific genes. In knock out 
experiments, Ikeda et al. showed that mice in which the SF-1 gene was disrupted exhibited 
grossly impaired ventromedial hypothalamic nucleus structure (Ikeda et al. 1995). Despite their 
apparently normal GnRH neurons, pituitary gonadotropins and GnRH receptor were not 
expressed. GnRH treatment restored gonadotropin and GnRH receptor expression in SF-1 
knock out mice. Curing with GnRH implies that impaired delivery of GnRH to the 
gonadotropes causes defects in gonadotropin and GnRH receptor expression. SF-1 knock out 
mice have defects in all three levels of the hypothalamus-pituitary-gonadal axis and this suggest 
that SF-1 plays a key role in reproductive function. Further studies on the link between SF-1, 
the hypothalamus and reproductive function will provide insight into the complex mechanisms 
of neuro-endocrine control. Recently the human gene encoding SF-1 has been cloned, which 
will provide new insights on SF-1 structure, thereby facilitating efforts to study the role of SF-1 
in neuro-endocrine control (Oba et al. 1996; Wong et al. 1996). 
2.8. DAX-1 
DAX-I encodes a 470 amino acid nuclear hormone receptor with a novel DNA-binding domain 
(Burris et al. 1996; Zanaria et al. 1994). Mutations in the DAX-I gene results in X-linked 
adrenal hypoplasia congenita and hypogonadotropic hypogonadism (Muscatelli et al. 1994). 
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Disruption of both the SF-1 and DAX-I genes results in a phenotype of adrenal insufficiency 
and deficiency of pituitary gonadotrophs (Ingraham et al. 1994; Luo et al. 1994; Yu et al. 
1996), but whereas Ftz-Fl-disrupted mice completely lack gonads, DAX-I null patients have 
poorly developed but detectable testes. Ito et al. (1997) showed that DAX-I inhibits SF-1-
mediated transactivation via a carboxy-terminal domain and suggests that the loss of this 
inhibitory property of DAX-I may account in part for the phenotype of adrenal hypoplasia 
congenita. DAX-I shows a similar tissue distribution to SF-I and is present in the pituitary 
gland, hypothalamus, adrenal gland, gonadotropes and gonads (Burris et al. 1995; Guo et al, 
1995). Burris et al. (1995) first described the presence of a putative SF-I site in the 5' -flanking 
region of the human DAX-I gene. They further showed that SF-1 is able to bind the putative 
SF-I response element found in the DAX-I promoter, in vitro. Yu et al. (1996) showed that 
DAX-I transcription is regulated by SF-I and in 1997 Vilain et al. showed that the SF-1-like-
site is an enhancer element within the DAX-I promoter. Taken together, these results suggest 
that SF-I may be transcription factor that acts, at least in part, through DAX-1 in the cascade 
leading to normal pituitary, adrenal, and gonadal development. 
In summary, sequence analysis of the regulatory region of the GnRH receptor gene has revealed 
the presence of a putative GSE or SF-1-like site. The aim of this study is to determine if SF-I 
interacts with the putative GnRHR GSE, and whether this interaction is involved in GnRH 
receptor gene regulation. Understanding the mechanisms by which the GnRHR is regulated has 
important therapeutic implications, as it is thought that regulation of the GnRHR gene is one of 
the major levels of control of reproductive function . 
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CHAPTER2 
MATERIALS AND METHODS 
1. Materials 
All materials (powders and orgaruc solvents) used were analytical grade, unless stated 
otherwise. Solutions were made with distilled-deionised H20 and sterilised by autoclaving. 
2. Cells 
Mouse pituitary gonadotrope precursor cell lines which expresses (aT3-l) (Windle et al. 1990) 
and which do not express (aT4) the GnRHR, as well as a mouse GnRH neuronal cell line 
(GTl-7) (Mellon et al. 1990) which may express the GnRHR under certain tissue culture 
conditions were obtained from Pamela Mellon (University of California, San Diego, CA). The 
mouse pituitary somatotrope cell line, GH3, as well as a monkey kidney cell line, COS- I, was 
used in this study. GH3 and COS-I cells were provided by the Department of Chemical 
Pathology, University of Cape Town. 
3. Plasmids 
A genomic clone, clone ill, of the mouse GnRH receptor gene was obtained from Stuart 
Sealfon at Mt. Sinai in New York. This clone contains 1.1 kb of the GnRH receptor gene 
cloned into the XbaI site of the pBluescript®SK phagemid. The 1.1 kb sequence is made up as 
follows: 500 bp of 5' -flanking sequence, 569 bp of coding sequence (accession number, 












Fig. 2.1. Plasmid map of clone III. Clone III contains 1.1 kb of GnRH receptor genomic 
sequence cloned into the Xbal site of pBluescript SK+. The white, black and grey boxes 
represent the 5 '-flanking region, exon 1 and intron 1, respectively. 
A 580 bp BglII-BamHI fragment was excised from clone ID after mutagenesis of the ATG to a 
BglII site. The constructs, wt GnRHR-LUC and mut GnRHR-LUC contain 563 bp of the 
GnRH receptor gene containing sequences from -500 to +63 relative to the transcription start 
with the wild type (TGTCCTTGG) or mutated (TGTTTTTGG) GSE respectively, cloned into 
the BglII site of the promoterless LUC reporter plasmid, pGL2-basic (Promega). The J3-
galactosidase expression vector, pCISLACZ, used in this study was provided by Dr. Arieh 
Katz, Department of Chemical Pathology, University of Cape Town, and has the lacZ gene (3 .8 
kb) cloned into the Xhol/Smal site of the 6.27 kb pCIS vector. The plasmid SF-I was obtained 
from Keith Parker (Duke University Medical Centre, Durrham, North Carolina) and contains 
about 2 kb of human SF-1 cDNA cloned into the EcoRI site of the 4.7 kb plasmid, pCMV5 
(Andersson et al. 1989). Human J3-actin cDNA (2.1 kb) cloned into the BamHI site of the 2.9 
kb ampicillin resistant expression vector Okayam<!-Berg (Okayama and Berg, 1983) was 
provided by Sihaam Boolay (Department of Biochemistry, University of Cape Town). 
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4. Oligonucleotides 
The sequences of oligonucleotides used are listed below: 
Oligonucleotides used for sequencing 
race 1 5' GAGGTGCCTGTCCGAAGTTCTCACC 3' 
m13 -20 5' GTAAAACGACGGCCAGT 3' 
T7 5' AATACGACTCACTATAG 3' 
T3 5' ATTAACCCTCACTAAAG 3' 
reverse pnmer 5' AACAGCTATGACCATG 3' 
GLl 5' TGTATCTTATGGTACTGTAACTG 3' 
GL2 5' CTTTATGTTTTTGGCGTCTTCCA 3' 
Oligonucleotides used for mutagenesis 
IS 5' CTTGGAGAAA GATCTCTAAC AATGCATC 3' 
2S 5' GAAGCCTGTT TTTGGAGAAA GATCTCTAAC AATGC 3' 
Double-stranded oligonucleotides used for mobility shift assays 
mGnRHR 'GSE' 5' GATCCCTGTCCTTGGAGAAGATC 3' 
3' CTAGGGACAGGAACCTCTTCTAG 5' GSE 
mGnRHR 5' GATCCCTGTTTTTGGAGAAGATC 3' 
mutated 'GSE' 3' CTAGGGACAAAAACCTCTTCTAG 5' mGSE 
SF-1 aromatase 5' GATCGATGACCTTGGGAGAGATC 3' 
3' CTAGCTACTGGAACCCTCTCTAG 5 SF-1 
Oligonucleotides were annealed for gel mobility shift assays using the method described by 
Ausubel et al. (1987). Complementary strands were annealed at a molar ratio of 1:1, by 
incubating at 88°C for 2 min, followed by 65°C for 10 min, 37°C for 10 min, 25°C for 5 min 
and then finally placing the sample on ice. 
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5. Plasmid isolation 
5.1. Small -scale (mini-prep) method 
The Ish-Horowicz and Burke method (1981) and the Wizard Minipreps DNA Purification kit 
were used to extract plasmid DNA Both methods employ the alkali-lysis method to isolate 
plasmid DNA 
5.1.1. Preparation of plasmid DNA using the Ish-Horowicz and Burke method 
Plasmid DNA was extracted from E. coli cells using a modified version of the miniprep method 
described by lsh-Horowicz and Burke (1981). The cells were grown overnight in 5 ml of 2 X 
yeast tryptone (2 X YT) (1.6% tryptone (w/v), 1% yeast extract (w/v), 85 .6 mM NaCl, pH 7.0) 
broth ( ampicillin 100 µg/ml) and incubated at 3 7°C, with shaking. Cells were harvested by 
spinning in a microfuge for 2 min and the cell pellet was resuspended in 200 µl of solution 1 (25 
mM Tris-Cl (pH 8.0), 50 mM EDTA, 1% glucose (w/v)). EDTA chelates Mg+ ions and 
therefore inactivates DNases, while glucose allows the formation of spheroplasts. Cells were 
lysed by adding 300 µl of freshly prepared solution 2 (0.2 M NaOH, 1% SDS (w/v)) and mixed 
by inverting the tube until the solution cleared. NaOH denatures chromosomal DNA, while 
SDS, a detergent, disrupts the cell membrane. After 5 min on ice 300 µl of solution 3 (3 M 
potassium acetate pH 4.8) was added and left on ice for a further 5 min. The decrease in pH 
allows selective renaturation of plasmid DNA that might have denatured after the addition of 
solution 2, while potassium acetate precipitates chromosomal DNA and proteins. Cellular debris 
was removed by spinning for 10 min at 15 000 g and the supernatant was transferred to a new 
tube. RNase A was added to a final concentration of 20 µg/ml and incubated at 37°C for 2 hr. 
After RNase treatment the supernatant was extracted twice with chloroform by adding an equal 
volume of chloroform, mixing by hand for 30 sec and then spinning for 1 min to allow phase 
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separation. The DNA was precipitated by adding an equal volume of 100% isopropanol to the 
aqueous phase and spinning for 10 min at 15 000 g. The DNA pellet was washed with 500 µl of 
cold 70% ethanol and centrifuged for 10 min. The pellet was vacuum dried and resuspended in 
32 µl of H20 . DNA was further purified by polyethylene glycol precipitation (PEG) as 
discussed in 5.3.2. 
5.1.2. Preparation of plasmid DNA using the Wizard DNA Purification kit. 
The protocol used was according to that described by the manufacturers (Promega). Cells were 
harvested from E. coli cultures as described in 5. 1. 1. The cell pellet was resuspended in 200 µl 
of Cell Resuspension Solution (50 mM Tris-Cl (pH 7.5), 10 mM EDTA, 100 µg/ml RNase A) 
and lysed by adding 200 µl of Cell Lysis Solution (0.2 M NaOH, 1 % SDS (w/v)). 
Chromosomal DNA and proteins were precipitated by adding 200 µl of Neutralisation Solution 
(1 .32 M potassium acetate pH 4.8) and spinning in a microfuge for 5 min. Wizard Minipreps 
DNA Purification Resin was added to the supernatant and plasmid DNA was isolated by 
passing the mixture through a Wizard minicolumn. The minicolumn traps plasmid DNA which is 
eluted with 50 µl of ultra-pure H20 . The plasmid DNA was analysed spectrophotometrically, 
then by restriction enzyme digestions and agarose gel electrophoresis. The concentration of the 
DNA was calculated according to the formula in Sambrook et al. (1989), where 1 absorbance 
unit at 280 nm is equivalent to 50 µg DNA/ml. The purity of the DNA was estimated by the 
ratio between the readings at 260 nm and 280 nm. The DNA was stored at -20°C. 
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5.2. Large-scale (maxiprep) method 
Plasmid DNA was extracted using a scaled-up version of the miniprep method of Ish-Horowicz 
and Burke, employing either the Nucleobond (Separations) or the Wizard Maxiprep DNA 
Purification kits. 
5.2.1. Extraction of plasmid DNA using the Nucleobond kit 
E. coli cells were grown in 10 ml of 2 X YT broth (ampicillin 100 µg/ml) at 37°C overnight, 
with shaking. A main culture (500 ml) was set up by diluting the starter culture 100-fold in 2 X 
YT broth (ampicillin 100 µg/ml) and incubating at 37°C overnight, with shaking. Cells were 
harvested by centrifugation at 5 000 rpm in a Beckman J2.21 centrifuge, JA-10 rotor. The cell 
pellet was carefully resuspended in 12 ml of solution SI (50 mM Tris-Cl (pH 8.0), 10 mM 
EDTA, 100 µg/ml RNase A). Cells were lysed by adding 12 ml of solution S2 (0.2 M NaOH, 
1% SDS (w/v)), mixed gently and incubated at room temperature for 5 min. Thereafter 12 ml of 
solution S3 (2.8 M potassium acetate pH 5.1) was added, the suspension mixed by inverting the 
tube 6-8 times and incubated on ice for at least 5 min. The cell suspension was centrifuged at 12 
000 rpm for 45 min at 4°C (JA-20 rotor). After the high speed centrifugation the supernatant 
was carefully removed from the white precipitate and loaded onto a NUCLEOBOND AX 
cartridge equilibrated with 5 ml of buffer N2 ( I 00 mM Tris, 15% ethanol, 900 mM KCl, pH 
6.3). After adsorption of the nucleic acid to the cartridge, it was washed twice with 12 ml of 
buffer N3 (100 mM Tris, 15% ethanol, 1159 mM KCl, pH 6.3). The plasmid DNA was eluted 
with 6 ml of buffer NS (100 mM Tris, 15% ethanol, 100 mM KCl, pH 8.5). The purified 
plasmid DNA was precipitated by adding 0.7 volumes of isopropanol followed by centrifugation 
at 15 000 rpm for 20 min at 4° (JA-20 rotor). The DNA was washed with 70% ethanol, vacuum 
dried for 5 min and redissolved in TE buffer (10 mM Tris-Cl (pH 7.5), I mM EDTA). The 
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DNA was analysed as described earlier and then purified by caesmm chloride (CsCl) 
centrifugation as discussed in 5. 3. 1. 
5.2.2. Extraction of plasmid DNA using the Wizard Maxiprep Purification kit 
Bacteria were grown up as for the Nucleobond kit. All steps were performed at room 
temperature. Cells were harvested as described in 5.2.1. The cell pellet was resuspended in 15 
ml of Cell Resuspension Solution (50 mM Tris-Cl (pH 7.5), 10 mM EDTA, 100 µg/ml RNase 
A). Cells were lysed by adding 15 ml of Cell Lysis Solution (0.2 M NaOH, 1% SDS (w/v)), 
mixed by inverting the tubes and left at room temperature until the solution cleared 
(approximately 15 min). Thereafter 15 ml of Neutralisation Solution (1.32 M potassium acetate 
pH 4.8) was added, mixed by inversion and centrifuged at 14 000 g for 30 min. The supernatant 
was removed and centrifuged for 15 min. The DNA was precipitated by adding one half volume 
of isopropanol and centrifuging at 14 000 g for 20 min. The DNA pellet was resuspended in 2 
ml of TE buffer. Ten ml of WIZARD Maxipreps DNA Purification Resin was added to the 
DNA solution and mixed. The Resin/DNA mix was transferred to a maxicolumn, with the tip 
inserted into a vacuum source. A vacuum was applied to pull the Resin/DNA mix into the 
maxicolumn. The maxicolumn was washed with 25 ml of column wash solution (0.2 M NaCl, 
20 mM Tris-Cl (pH 7.5), 5 mM EDTA, 55% ethanol). The resin was rinsed by adding 5 ml of 
80% ethanol to the maxicolumn. After the ethanol was drawn into the maxicolumn, the vacuum 
was allowed to draw for a further minute. The maxicolumn was inserted into a 50 ml tube and 
centrifuged at 1 500 g for 5 min in a swinging bucket rotor to dry the resin. The maxicolumn 
was placed back onto the vacuum source and the resin dried to completion by drawing a 
vacuum for another 5 min. Preheated (70°C) TE buffer (1.5 ml) was added to the maxicolumn 
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and left for 1 min. The DNA was eluted by centrifuging at 1 500 g for 5 min. The plasmid DNA 
was analysed as described before and thereafter purified by CsCl centrifugation. 
5.3. Purification of plasmid DNA 
5.3.1. CsCI centrifugation 
Plasmid DNA was purified by isopycnic gradient centrifugation (CsCl centrifugation) as 
described in Sambrook et al. (1989). Ethidium bromide is a DNA intercalating agent that inserts 
between adjacent base pairs in the DNA double helix and reduces the buoyant density by pulling 
the strands apart. Covalently closed circular plasmid DNA cannot intercalate as much Ethidium 
Bromide as linear DNA can, and therefore a differential gradient is produced, which allows the 
separation of DNA in a solution ofCsCl (Fig. 2.2). 
protein ------------,_ ... ._ .. 
nicked circular · ·. <=J ........... "'., 
•· • '. ~ ._s.~· • ,~.; •, , . 
or linear DNA -------------~-• closed circular -:,.:, · .• · ·· 
plasmid DNA ------
Fig. 2.2. Separation of DNA in a CsCl-Ethidium Bromide gradient (Sambrook et al. 1989). 
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The DNA to be purified (approximately 1 mg) was added to a solution consisting of 12.6 g of 
CsCl, 12.3 ml of TE buffer and 300 µ1 of 10 mg/ml ethidium bromide in a centrifuge tube. The 
weight of the DNA solution was adjusted so that I ml equalled 1.56 g. Beckman Quickseal 
ultracentrifuge tubes (Vti65) were filled with the plasmid DNA solution and centrifuged at 45 
000 rpm overnight (20°C) in a Beckman L-70 ultracentrifuge, Vti65 .2 rotor. The plasmid band 
was visible in normal light. The Vti65 tube was punctured and the closed circular plasmid DNA 
removed with a I ml syringe and placed into a IO ml tube. Ethidium bromide was removed by 
extracting four times with two volumes of isoamyl alcohol. After the fourth extraction 6 ml of 
TE buffer was added to the aqueous phase and dialysed for 3 hr against three changes of 500 ml 
TE buffer. After dialysis the DNA was precipitated by adding one tenth volume of 3 M sodium 
acetate (pH 5.2) and 2.5 volumes of cold 100% ethanol, and placed at -20°C overnight. The 
DNA was collected by centrifugation at 14 000 g for 30 min. The pellet was washed with cold 
70% ethanol and centrifuged for 15 min. After the pellet was vacuum dried it was resuspended 
in 200-500 µ1 of TE buffer. The DNA was analysed as described before and then stored at -
20°C. 
5.3.2. PEG precipitations 
Differential precipitation with PEG yields plasmid DNA of extremely high purity but unlike 
CsCl purification, does not efficiently separate nicked circular molecules from the closed 
circular form of the plasmid DNA (Sambrook et al. 1989). Miniprep DNA prepared by the 
alkali-lysis method as described in section 5. 1.1. was purified by PEG precipitation and then 
used for DNA sequencing . 
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One quarter volume (8 µl) of 4 M NaCl and one and a quarter volume ( 40 µl) of 13% PEGsooo 
was added to the 32 µl of plasmid DNA isolated in 5.1.1. After thorough mixing the samples 
were incubated on ice for 40 min and the DNA pelleted by centrifugation at 15 000 g for 20 min 
at 4°C. After aspirating off the supernatant, the pellet was rinsed with 500 µI of cold 70% 
ethanol and centrifuged for 10 min. The supernatant was decanted, the DNA pellet vacuum 
dried for 10 min and then resuspended in 20 µl of H20 . The DNA was analysed 
spectrophotometrically, then by agarose gel electrophoresis and stored at -20°C. 
6. Restriction enzyme digestion 
Restriction enzyme digestions were carried out usmg restriction buffers and enzymes as 
recommended by the manufacturers (Boehringer Mannheim and Amersham). The volume of 
enzyme used never exceeded one tenth of the total reaction volume as the enzyme contains 
glycerol, which may inhibit the reaction. Two restriction enzymes could be combined in a single 
digest provided their buffer requirements were compatible. If their buffer requirements were 
incompatible, the DNA was first digested with one enzyme, ethanol precipitated and then 
digested with the second enzyme. Digestion volumes varied according to the amount of DNA 
being digested, but normally 0.5 µg of plasmid DNA was digested in a total volume of 10 µl 
using 5 units of enzyme. Digestions were incubated at 3 7°C for 2-16 hr. The reactions were 
terminated by adding one sixth volume of 6 X stop/loading buffer (50% glycerol (v/v), 100 mM 
EDTA (pH 8.0), 1% SDS (w/v), 0.1% bromophenol blue (w/v), 0.1% xylene cyanol (w/v)) and 
analysed by agarose gel electrophoresis. 
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7. Agarose gel electrophoresis 
To separate, identify and purify DNA fragments agarose gel electrophoresis was used. When an 
electric field is applied across an agarose gel, DNA, which is negatively charged, migrates 
toward the anode at a rate proportional to its size (Sambrook et al. 1989). 
Agarose gel electrophoresis was performed using 1-4% agarose gels, depending on the size of 
the DNA fragments to be separated. Agarose (Sigma) was dissolved in 1 X TAE (0.04 M Tris-
acetate, 0.001 M EDTA) buffer by heating in a microwave oven until the solution became clear. 
Ethidium bromide was added to the gel to a final concentration of 0.5 µg/ml to enable 
visualisation of the DNA by transillumination. It was cooled to approximately 50°C before 
being poured into a horizontal mold and allowed to solidify for 30-60 min. Thereafter DNA 
samples ( containing stop/loading buffer to a final concentration of 1 X) were loaded onto the 
gel submerged in a buffer tank containing 1 X T AE. An electric field of approximately 10 V / cm 
was applied to the various gels. Bacteriophage 11, DNA digested with Pstl was used as a 
molecular size marker, or when very small fragments were analysed the 123 bp ladder 
(Boehringer Mannheim) was used. Preparative agarose gels (DNA fragments for cloning or 
radioactive labelling) were performed with 1-2% low melting agarose gels in 1 X T AE buffer 
(SeaPlague (FMC BioProducts) for large fragments or NuSieve (FMC BioProducts) for small 
fragments less than 1 kb). Preparative gels were run in 1 X TAE buffer at 5 V/cm. The bands 
were detected as above, but with a low energy hand-held UV lamp (11,=342nm) to ensure that 
the DNA was not damaged. 
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8. Purification of DNA fragments from low melting agarose 
DNA was recovered from low melting agarose gels using the USBioclean MP Kit (United State 
Biochemical), which is based on the method of Vogelstein and Gillepsie (1979). After 
separation by agarose gel electrophoresis, the relevant bands were cut out with sterile blades 
after visualisation by a hand-held UV lamp (A=342nm). The gel slices were placed in petri 
dishes, cut up, and transferred to 1.5 ml microfuge tubes. Three volumes of 6 M NaI solution 
were added to the agarose gel block and placed at 55°C for 5 min to dissolve the agarose. 
Thereafter 10 µl of glass powder suspension was added, mixed well, and allowed to sit on ice 
for 5 min to allow the DNA to adhere. The mixture was then microfuged for 10 sec and the 
supernatant removed. The glass powder pellet was washed twice with a SO-fold excess of rinse 
buffer and microfuged for 10 sec. The DNA was eluted by dissolving the glass powder pellet in 
20 µl of TE buffer and incubating at 55°C for 5 min. After incubation the sample was 
microfuged for 10 sec and the DNA was recovered in the supernatant. The DNA concentration 
was estimated by ethidium bromide spotting (Sambrook et al. 1989), which entails spotting 
DNA samples and standards onto the surface of a I% agarose slab gel containing 0.5 µg/ml 
ethidium bromide and then visualising by UV light. Solutions of A DNA, with concentrations 
varying between 2.5 and 25 ng/µl, were used as standards. 
9. DNA cloning 
9.1. Preparation of competent ceUs 
Competent cells were prepared using a variation of the method described by Perbal (1988). 
Cells were streaked onto LB (1 % tryptone (w/v), 0.5% yeast extract (w/v), 171 mM NaCl, pH 
7.0) agar plates and grown at 37°C overnight. Thereafter a single colony was inoculated into 40 
ml of \j/ broth (2% tryptone (w/v), 0.5% yeast extract (w/v), 20 mM MgS04.7H20, IO mM 
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NaCl, 5 mM KCl) and grown at 37°C overnight, with shaking. 4 ml of the overnight culture 
was inoculated into 200 ml of \j/ broth and shook at 37°C until the OD6oo reached 0.46-0.60. All 
further steps were carried out at 4°C. Cells were collected by spinning at 5 000 rpm for 10 min 
(Beckman 12.21 centrifuge, JA-10 rotor). The cell pellet was resuspended into 40 ml of pre-
cooled TFBI buffer (30 mM potassium acetate, 100 mM RbCh, 10 mM CaCh.2H20 , 50 mM 
MnCh.4H20, 15% glycerol (v/v), pH 5.8). The solution was spun at 5 000 rpm for 10 min (JA-
20 rotor) and the cell pellet was resuspended into 8 ml of TFBII buffer (10 mM MOPS, 75 mM 
CaCh.2H20, 10 mM RbCh, 15% glycerol, pH 6.8). The solution was left on ice for 15 min, 
then frozed down and stored in 400 µl aliquots at -70°C. 
9.2. Linearisation and dephosphorylation of vector 
Recircularisation of vectors was minimised by removing the 5' phosphates with calf intestinal 
phosphatase (CIP) (Boehringer Mannheim). The method used is described in Sambrook et al. 
(1989) and is as follows: vectors (20 µg) were linearised by digesting overnight with 60 units of 
a suitable enzyme. After digestion the sample was extracted with an equal volume of phenol-
chloroform (1: 1 v/v) and the DNA precipitated by adding 2 volumes of 100% ethanol and 
placing at 0°C (an ice-water slurry) for 15 min. The DNA was recovered by spinning at 15 000 
g for 10 min at 4°C and the DNA pellet was redissolved in 90 µl of 10 mM Tris-Cl (pH 8.0). 
The concentration of the DNA was determined spectrophotometrically and the DNA was 
dephosphorylated in a reaction containing I X dephosphorylation buffer (Boehringer 
Mannheim) and 0.2 units of CIP. The reaction was placed at 56°C and stopped after 30 min by 
adding 5 µl of 10% SDS (w/v) and 1 µl of 0.5 M EDTA (pH8.0). After mixing well the CIP 
was inactivated by placing at 75°C for 10 min. The reaction was cooled to room temperature 
then extracted once with an equal volume phenol and then with an equal volume of phenol-
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chloroform (1 : 1 v/v). The DNA was precipitated by adding one tenth volume of 3 M sodium 
acetate (pH 7.0), 2 volumes of 100% ethanol and placed at 0°C for 15 min. The DNA was 
recovered by centrifugation at 15 000 g for 10 min, the pellet washed with 70% ethanol and 
centrifuged for a further 10 min. The DNA was resuspended in 60 µl of TE buffer and the 
concentration determined. 
9.3. Ligation 
Ligation reactions were performed using the in-gel-ligation method described in the NuSieve 
GTG agarose booklet, with slight modifications. The molar ratio of insert: vector used was 5: 1. 
25 ng of insert DNA was ligated to 48 ng of vector DNA in a reaction consisting of 1 X T4 
ligase buffer (Boehringer Mannheim) and 4 units T4 DNA ligase (Boehringer Mannheim) in a 
final volume of 42 µl. The ligation reaction was incubated at room temperature for 16 hr. 
Reactions were incubated at 68°C for 5 min to melt the agarose and ligations stopped by adding 
EDTA to a final concentration of 12.5 mM. The samples were placed at 37°C until 
transformation to prevent the agarose from solidifying. 
9.4. Transformation 
The transformation method used was a variation of the method described in the Sambrook et al. 
(1989). E.coli XL-1 blue competent cells were thawed on ice and 10 µl of the ligation mix, 
prepared in section 9.3 (approximately 10 ng of vector) was added to 100 µl of the competent 
cells prepared in 9.1. Two controls were set up in parallel; a transformation control, i.e., 
competent cells transformed with 1.25 ng of uncut pBR322 and a contamination control, i.e., 
cells without DNA After 30 min on ice cells were heat-shocked (37°C for 5 min) to induce 
DNA uptake and then placed on ice for 2 min. 0.9 ml of LB medium was added and the 
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reactions incubated at 3 7°C for 60 min, with shaking, to allow expression of the antibiotic 
resistance markers. Different aliquots of the transformation mixes were plated onto LB agar 
plates ( ampicillin 50 µg/ml; tetracycline 15 µg/ml) and incubated at 3 7°C overnight. 
Recombinants were screened by miniprep plasmid isolation, restriction enzyme digestion, 
agarose gel electrophoresis and DNA sequencing. 
10. DNA sequencing. 
Sequencing was performed using the Sequenase 2.0 kit (United States Biochemical) or an 
automated DNA sequencer (373 DNA Sequencer, Applied Biosystems). 
10.1. Sequencing using the Sequenase 2.0 (USB) kit 
The Sequenase 2.0 kit is based on the enzymatic method described by Sanger et al. (1977). This 
method involves the use of dideoxynucleoside triphosphates ( ddNTP) that, once incorporated 
into a growing chain prevent further extension because they lack the necessary 3 ' -hydroxyl 
group. Four reactions, each containing all four dNTPs ( one radioactively labelled), are carried 
out. DNA polymerase may incorporate either a dNTP or a ddNTP into the growing chain. If a 
ddNTP is incorporated, chain elongation is terminated and this results in a population of DNA 
strands of various lengths, each ending with the same ddNTP. The DNA sequence can be 
deduced, after these fragments have been resolved, according to size, by electrophoresis on a 
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Fig. 2.3. Dideoxy reaction for sequencing. Copying of the insert DNA by DNA polymerase is 
inhibited at specific sites in the presence of dideoxynucleotides (Sambrook et al. 1989). 
The protocol supplied with the Sequenase 2.0 kit was followed, with slight modifications. 
Double-stranded plasmid DNA was denatured using 2 different methods. 
10.1.1. Alkaline denaturation 
The method used is described in the Isotherm DNA sequencing kit. Approximately 5 µg of 
DNA, in a total volume of 20 µl, was denatured by adding an equal volume of 0.4 M NaOH, 
0. 4 mM EDT A The reaction was mixed and incubated at 65°C for 15 min. The denatured DNA 
was precipitated by adding one fifth volume of 2 M ammonium acetate and 5 volumes of 95% 
ethanol, followed by incubation at room temperature for 5 min. The DNA was collected by 
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spinning at 15 000 g for 5 min and the DNA pellet washed by centrifuging with 70% ethanol. 
The pellet was dried in a speedy vac and resuspended in 7 µl ofH20 . 
10.1.2. Denaturation by boiling 
The template DNA was denatured by boiling 5 µg of DNA, in a total volume of 7 µl , for 3 min. 
The DNA was then immediately placed on dry ice for 30 sec and pelleted in a microfuge (Yuh-
man Sun, personal communication). 
The denatured DNA was annealed to different primers, with concentrations ranging between 
10-20 ng, in a reaction mixture consisting of7 µl of DNA, 2 µl of 5 X reaction buffer (20 mM 
Tris-Cl (pH 7.5), 100 mM MgCh, 250 mM NaCl) and lµl of primer. The annealing reaction 
was allowed to proceed at 3 7°C for 15 min then placed on ice ( not longer than four hours) until 
the labelling reaction. The labelling reaction was carried out by adding 2 µl of 5 X dGTP 
labelling mix (all dNTPs except dATP), 1 µl of 100 mM DTT, 2 µl of Sequenase diluted 8-fold 
with enzyme dilution buffer and 0.5 µl of [a-35S] dATP (10 µCi/µl , Amersham). The 
components were mixed and incubated at room temperature for 2 min. During incubation tubes 
containing 2.5 µl of the four termination mixes, ddATP, ddCTP, ddGTP and ddTTP were 
prewarmed at 3 7°C for at least 1 min. After labelling 3. 5 µl of the labelling reaction was 
transferred into each of the microfuge tubes containing the four termination mixes. The 
components were mixed by gentle agitation and incubated at 3 7°C for 5 min before the addition 
of 5 µl of stop buffer (95% formamide (v/v), 20 mM EDTA, 0.05% bromophenol blue (w/v), 
0.05% xylene cyanol FF (w/v)). The samples were stored at -20°C until polyacrylamide gel 
electrophoresis. 
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11. Denaturing polyacrylamide gel electrophoresis 
DNA fragments were separated by polyacrylamide gel electrophoresis (Sambrook et al. 1989). 
A 6% polyacrylamide gel was prepared by mixing 5.7 g acrylamide (Merck), 0.3 g bis-
acrylamide (Sigma), 42 g urea, 20 ml 5 X TBE (0.45 M Tris-borate, 0.01 M EDTA), 40 ml 
H20 , and stirrring with a magnetic stirrer for 1 hour. The solution was filtered through a 
scintered glass funnel under vacuum. Polymerisation was initiated by adding 800 µl of 10% 
ammonium persulfate (w/v) and 80 µl of N,N,N' ,N' Tetramethlyethylenediamine (TEMED) 
before pouring the gel. After polymerisation (approximately 45 min) the gel was covered with 
Saran wrap and kept overnight, or used immediately. The gel was placed in an electrophoresis 
apparatus, containing 1 X TBE (0.09 M Tris-borate, 0.002 M EDTA), allowing the gel to be 
bathed in buffer. The gel was preheated at 90 watts for 30 min. Samples were denatured by 
placing at 80°C for 2 min prior to being loaded and electrophoresed at 90 watts for 1.5 to 4 hrs 
depending on where the sequence of interest was situated from the primer. Sequences were 
determined by autoradiography. 
12. Autoradiography 
Both denaturing gels (DNA footprinting and sequencing gels) and non-denaturing PAGE gels 
(gel mobility shift assays) were vacuum dried onto Whatman 3MM blotting paper before 
exposing to X-ray films. For gels containing 32P isotope, the films (Hyperfilm, Amersham) were 
exposed to the gel in the presence of an intensifying screen at -70°C. Intensifying screens were 
not necessary if 35S was used and exposure was performed at room temperature. Exposure 
times ranged from overnight to 1 week. After exposure, X-ray films, having been exposed to 
the gel in a light-excluding cassette, were removed and placed in developing solution. After 2 
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min the film was transferred to water for 1 min then to a fixing solution for a further 2 min. The 
X-ray film was rinsed with water and hung up to air dry. 
13. Mutagenesis 
Site-directed mutagenesis of the putative SF- I site in the 5 ' -flank of the mouse GnRH receptor 
gene was performed using a variation of the method described by Kunkel (1985). 
13.1. Preparation of single-stranded target DNA 
Uracil containing single-stranded DNA was prepared by transforming clone ill into competent 
CJ236 E. coli cells (dufung), and the transformations were plated onto LB antibiotic plates 
(ampicillin 100 µg/ml , chloramphenicol 30 µg/ml) . After overnight incubation at 37°C a single 
colony was inoculated into 2 ml of 2 X YT broth (ampicillin 100 µg/ml , chloramphenicol 30 
µg/ml) and shaken at 3 7°C overnight. Thereafter 20 µl of the overnight culture was added to 4 
ml of 2 X YT broth (ampicillin 100 µg/ml , chloramphenicol 30 µg/ml , uridine 0.25 µg/ml) , 
incubated at 37°C with shaking until the OD60o equalled 0.5-0.8 and then 1 ml was added to 1 
ml of 2 X YT broth (ampicillin 100 µg/ml , chloramphenicol 30 µg/ml , uridine 0.25 µg/ml) , 
infected with 5 µl ofVCS M13 helper phage (Strategene, >10
11 pfu/ml) and shaken at 37°C for 
1 hr. This was inoculated into 25 ml of 2 X YT broth (ampicillin 100 µg/ml , uridine 0.25 
µg/ml, 70 µg/ml kanamycin), and grown at 3 7°C overnight, with shaking. Phage-infected cells 
were harvested by spinning at 8 000 rpm for 30 min at 4°C (Beckman JA 2.1, JA-20 rotor). The 
supernatant, containing the phage, was removed and centrifuged as before. The phage was 
precipitated with one fifth volume of 5 X PEG/NaCl (15% PEG8000 (w/v), 2.5 M NaCl) and 
incubated on ice for 1 hr. Thereafter, it was centrifuged at 8 000 rpm for 15 min at 4°C. The 
pellet was drained well and resuspended in 3 ml of pre-cooled (4°) TE buffer by vigorous 
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vortexing. The sample was divided into 750 µl aliquots and placed on ice for 1 hr. Thereafter it 
was centrifuged as before and the supernatant was extracted once with an equal volume of 
phenol, followed by extraction with an equal volume of phenol-chloroform-isoamylalcohol 
(25:24: 1, v/v)) and then twice with an equal volume of chloroform-isoamylalcohol (24: 1, v/v). 
Samples were pooled and uracil containing single-stranded DNA was precipitated by adding 
one volume of 3M sodium acetate (pH 5.2) and 2.5 volumes of 100% ethanol and placed at -
20°C overnight. DNA was collected by spinning at 15 000 g for 30 min, the pellet washed with 
70% ethanol and centrifuged for 10 min. The pellet was air dried for 10 min and resuspended in 
100 µl of TE buffer. The uracil containing single-stranded DNA was analysed 
spectrophotometrically and by agarose gel electrophoresis. 
13.2. Hybridisation of oligonucleotides to the uracil containing single-stranded DNA 
(USS) and primer extension 
Polynucleotide kinase (PNK) was used to phosphorylate oligonucleotides IS and 2S (section 
2.4). Oligonucleotides (50 pmol) were kinased in a reaction containing 50 mM Tris-Cl (pH 7.6), 
10 mM MgCh, 0.1 mM EDTA, 2 mM DTT, 0.1 mM spermidine HCl, 0.5 mM ATP and 10 
units of PNK in a final volume of 20 µl. Reactions were incubated at 3 7°C for 60 min. PNK was 
inactivated by placing at 68°C for 10 min. Oligonucleotides were annealed to the uracil 
containing single-stranded DNA by mixing 1.5 pmol of template DNA, 15 pmol of either IS or 
2S and 1 µl of 10 X PEI buffer (100 mM Tris-Cl (pH 7.5), 100 mM MgCh, 500 mM NaCl, 
100 mM DTT) in a final reaction volume of 10 µl and placed at 70°C for 5 min. The reaction 
was cooled down to 30°C, placed on ice, and the uracil containing single-stranded DNA was 
converted to a full length, circular DNA strand by polymerisation and ligation. Polymerisation 
was initiated by adding the following to the annealing reaction; I µI of IO X PE 2 buffer (200 
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mM Tris-Cl (pH 7. 5), I 00 mM MgCh, I 00 mM DTT), 2 µI of 5 mM dNTPs, I µl of 10 mM 
ATP, 0.5 units of T7 DNA polymerase (Boehringer Mannheim) and I unit of T4 DNA ligase 
(Boehringer Mannheim). The components were mixed carefully and the reaction was placed on 
ice for 5 min, followed by 5 min at room temperature and 2 hr at 3 7°C. The reaction was 
stopped with 20 µl of 10 mM Tris-Cl (pH 7.6) and 20 µl of 10 mM EDTA. A polymerisation 
reaction with no oligonucleotide was used as a control. Polymerisation reactions were analysed 
by agarose gel electrophoresis and transformed into E. coli XLl blue cells. Colonies were 
screened by miniprep plasmid isolation and restriction enzyme digestion. Mutations were 
confirmed by DNA sequencing. 
14. Radiolabelling of DNA 
Two methods were employed to label DNA 
14.1. Labelling with Kienow 
DNA fragments for DNase I footprinting and double-stranded oligonucleotides for mobility 
shift assays were end-labelled using the Kienow subunit of DNA polymerase I (United States 
Biochemical). Reactions were performed as described by Sambrook et al. (1989). Generally 100 
ng of DNA was labelled in a reaction consisting of 1 X Kienow reaction buffer (United States 
Biochemical), 20 µCi of a-
32P dCTP (10 µCi/µl , Amersham) and I unit of Kienow in a final 
reaction volume of 20 µl. Reactions were incubated at 3 0°C for 15 min then stopped with I µI 
of 0.5 M EDTA. Labelled DNA was purified by spinning through a Sephadex G-50 spin 
columm. 
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14.2. Megaprime labelling 
Radioactive probes for Northern blot analysis were labelled using the protocol supplied with the 
Megaprime TMDNA labelling kit (Amersham), which is based on the method of Feinberg and 
Vogelstein (1984). This method uses random sequence hexanucleotides to prime DNA synthesis 
on denatured template DNA at numerous sites along its length. By substituting a radiolabelled 
nucleotide for a non-radioactive equivalent in the reaction mixture the newly synthesised DNA 
is made radioactive. 
DNA fragments to be labelled were electrophoresed on low melting agarose gels as described in 
section 2.7. The desired band was excised from the gel and 3 ml of H20 was added for every 
gram of agarose. The sample was placed in a boiling H20 bath for 5 min to melt the agarose and 
denature the DNA Primer solution ( 5 µl) was added to 25 ng of denatured DNA in a total 
volume of 26 µl and boiled for 5 min. The reaction was spun down and the following added: 4 
µl of dATP, 4 µl dGTP, 4 µ1 of dTTP, 5 µl of 10 X reaction buffer (Tris-Cl (pH 7.5), MgCh, 2-
mercaptoethanol), 2 µl of Kienow and 5 µl of a-
32P dCTP (10 µCi/µl, Amersham) in a total 
volume of 50 µI. The components were mixed gently and placed at 37°C for 30 min. The 
reaction was stopped with 5 µ1 of O .2 M EDT A and purified by spinning through a Sep had ex G-
50 spin column. 
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14.3. Purification of labelled DNA 
The labelled DNA was separated from unincorporated nucleotides using a Sephadex G-50 spin-
column, which was prepared as follows: 
A 1 ml disposable syringe was plugged with a small amount of sterile glass wool and filled with 
Sephadex G-50 (equilibrated with STE buffer (0.1 M NaCl, 10 mM Tris-Cl (pH 8.0), 1 mM 
EDTA)) to 0.9 ml. The column was washed thrice with 100 µl of STE buffer by centrifuging 
for 1 min at 4 000 gin a low speed benchtop centrifuge (Lasec). The labelled DNA was made 
up to a volume of 100 µI with STE buffer and then applied to the column. Labelled DNA was 
eluted from the column by centrifugation at 4 000 g for 1 min. Specific activity of the fragments 
were typically 40 000-100 000 cpm/ng, as determined by counting 1 µl in a scintillation counter. 
15. Preparation of nuclear extracts 
Nuclear extracts were prepared according to the method described by Schreiber et al. (1989). 
All steps were carried out at 4°C. 1.0-5 .0 x106 tissue culture cells were harvested by first 
washing cells with 10 ml of cold phosphate-buffered saline (PBS) (10 mM Na2HP04, 1.75 mM 
KH2P04, 137 mM NaCl, 2.7 mM KCl), and then scraping the cells off the flasks with a rubber 
policeman. Cells were pelleted by centrifugation (800 g for 5 min) and then and stored at -70°C 
until nuclear extract preparation. To make nuclear extracts the cell pellets were allowed to thaw 
on ice and then washed with 10 ml of TRIS-buffered saline (TBS) (25 mM Tris, 137 mM NaCl, 
2 .7 mM KCl, pH 7.4) by centrifuging at 800 g for 5 min. The cell pellet was resuspended in 1 
ml of TBS, transferred to an eppendorf tube and pelleted by spinning for 15 secs in a microfuge. 
The TBS was removed and the cell pellet was resuspended in 400 µl of cold buffer A (10 mM 
HEPES (pH 7.9), 10 mM KCI, 0.1 mM EDT A, 0.1 mM EGT A, 1 mM DTT, 0.5 mM PMSF) 
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by gentle pipetting with a yellow tip. The cells were allowed to swell by placing on ice for 15 
min, after which 25 µl of a 10% (v/v) solution of Nonidet NP-40 was added and the tube 
vigorously vortexed for 10 sec. The reaction was spun for 30 sec in a microfuge and the nuclear 
pellet was resuspended in 50 µl of cold buffer C (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM 
EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF). Thereafter the sample was vigorously rocked 
for 15 min. Nuclear extracts were centrifuged for 5 min at 12 000 g in a microfuge and the 
supernatant stored in aliquots at -70°C. 
16. Mobility Shift Assays 
Mobility gel shift assays were performed according to the method described by Hom et al. 
(1992). Variable amounts of nuclear extracts were incubated in standard incubation buffer. The 
final reaction conditions were 37.5 mM KCl, 100 mM NaCl, 7.5 mM HEPES, 10 mM Tris-Cl 
(pH 8.0), 8.125% (v/v) glycerol, 1.25 mM MgCh, 3.5 mM DTT, 0.675 mM PMSF, 1 mM 
EDTA, 0.25 mM EGTA, 2 µg pdldC (Boehringer Mannhein) as non-specific competitor, 20 µg 
Bovine Serum Albumin (Molecular Biology grade, Boehringer Mannheim) and 1 ng of end-
labelled DNA Reactions were started by adding nuclear extracts and were carried out in a total 
volume of 20 µl for 10 min at room temperature. To resolve the complexes, the reaction 
mixtures were applied to 4% polyacrylamide gels (29: 1 acrylamide:bisacrylamide) in 0.25 X 
TRIS-acetate-EDTA (pH 8.0) (TAE) buffer. Gels were pre-electrophoresed at 150 V for 2 hr 
at room temperature. Before the samples were loaded onto the gel, the pre-electrophoresis 
buffer was changed and electrophoresis was continued at 150 V for 2-3 hr at room temperature. 
Gels were dried and the DNA-protein complexes were visualised by autoradiography. The 
binding specificities of the GSE/SF-1 oligonucleotides were determined by using double-
stranded DNA oligonucleotides as unlabelled competitors in the mobility shift assay. The 
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mobility shift incubations were carried out as above, however, the DNA competitors were 
included in the reaction cocktail. The molar ratio of competitor to labelled DNA used was 
100: 1. 
17. DNase I footprinting 
The DNase I footprint was performed as described by Hapgood and Patterton (1994) with 
slight modifications. Radiolabelled DNA fragments were incubated with variable amounts of 
nuclear extract. Final reaction conditions were 37.5 mM KCl, 60 mM NaCl, 6.5 mM HEPES, 
10 mM Tris-Cl, 8.5% (v/v) glycerol, 1.75 mM MgCh, 4.7 mM DTT, 0.605 mM PMSF, 1 mM 
EDTA, 0.15 mM EGTA, 2 µg pdldC, 40 µg BSA and 1 ng of end-labelled DNA in a total 
volume of 40 µl. Reactions were started by adding nuclear extracts and the DNA-protein 
mixture was incubated at room temperature for 10 min then placed at 4°C for at least 5 min. 
The sample was adjusted to 19 mM MgCh and 19 mM Ca Ch, by adding 1. 5 µl of O. 5 M MgCh; 
0.5 M CaCh, before adding 3 µl of 16 µg/ml DNase I (grade 1, Boehringer Mannheim). The 
reaction was allowed to proceed at 4°C for exactly 1 min and then stopped by adding 8.4 µl of 
stop solution (0.7 mg/ml ofproteinase K, 0.12 M EDTA, 1% (w/v) SDS) and placed at 37°C 
for 30 min. Thereafter one tenth volume of 3M sodium acetate pH 5.2 was added and proteins 
were extracted by adding an equal volume of phenol-chloroform-isoamylalcohol (25 :24: 1, v/v) 
at room temperature. Reactions were vortexed for 30 sec and microfuged for 2 min. The 
phenol-chloroform-isoamylalcohol extraction was repeated. The DNA was precipitated by 
adding 150 µl of 100% ethanol, vortexing and placing at -70°C for 30 min. The DNA was 
collected by spinning at 15 000 rpm in a microfuge for 30 min at 4°C. The pellet was washed 
with 200 µI of 70% ethanol and centrifuged for 10 min. Samples were vacuum dried and 
resuspended in 3 µl of sequencing loading buffer (Sequenase 2.0 kit, Amersham). Samples were 
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stored at -20°C or immediately electrophoresed. They were denatured by placing at 90°C for 3 
min, then subjected to electrophoresis on a 6% denaturing polyacrylamide gel for 1.5 hr. Gels 
were dried and DNA footprints were detected by autoradiography. 
18. RNA isolation 
RNA was extracted under RNase free conditions. All solutions were treated with Diethyl 
pytocarbonate (DEPC) and latex gloves were worn at all times. RNA was extracted from tissue 
culture cells using the acid-guanidinium-thiocyanate-phenol-chloroform method (Sambrook et 
al. 1989). All steps were carried out at 4°C. Eukaryotic cells growing in 75 cm2 flasks were 
harvested with a rubber policeman, washed with cold PBS and transferred to 15 ml centrifuge 
tubes. Cells were pelleted by spinning at 800 g for 3 min. The pellet ( approximately 5 x 106 
cells) was resuspended in 1 ml of PBS and divided into 250 µl aliquots in microfuge tubes. An 
equal volume of solution D (4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7.0), 
0.5% (w/v) sarcosyl, 0.72% mercaptoethanol) was added, homogenised with a 1ml syringe and 
stored at -70°C until RNA extraction. RNA extraction was continued at 4°C by adding 25 µl of 
2 M sodium acetate (pH 4.0), 250 µl of phenol and 50 µl of chloroform-isoamylalcohol (24: 1, 
v/v) to each sample. After mixing, the samples were left on ice for 1 hr, then centrifuged at 10 
000 g for 20 min. RNA was precipitated by adding an equal volume of isopropanol, placing on 
dry ice for 10 min, then spinning as before. The pellet obtained was resuspended in 150 µl of 
solution D and the RNA precipitated as before. The RNA pellet was washed with 75% ethanol 
by spinning at 10 000 g for 10 min at 4°C. It was briefly dried under vacuum, then resuspended 
in 25 µl of DEPC-treated H20 by placing at 65°C for 10 min. The RNA concentration was 
determined spectrophotometrically where 1 absorbance unit at 260 nm equals 40 µg/ml . The 
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purity of the RNA was determined by the 260/280 ratio . The integrity of the RNA was analysed 
on a I% formaldehyde containing agarose gel. 
18.1. RNA gel electrophoresis 
For RNA gels the electrophoresis apparatus was washed with DEPC-treated H20 . RNA 
samples were analysed on I% formaldehyde containing agarose gels based on a modification of 
the method described in Ausubel et al. (1987). For a minigel, gels were prepared as follows: 0.5 
g agarose, 5 ml 10 X MOPS (0.4 M morpholinopropanolsulfonic acid, 100 mM sodium acetate, 
10 mM EDTA, pH 6.0) and 36 ml DEPC-H20. The agarose was heated and allowed to cool to 
approximately 50°C before adding 8.5 ml 37% (v/v) formaldehyde. The gel was poured in a 
fume cupboard. After the gel had solidified it was covered with 1 X MOPS buffer and the RNA 
samples were loaded. RNA samples were dried in a speedy vac and resuspended in IO µl of 
loading buffer. Loading buffer was always made fresh and included 72 µl offormamide, 16 µl of 
10 X MOPS, 26 µl of 37% (v/v) formaldehyde, 8 µl of DEPC-H20 , 10 µl of 80% (v/v) 
glycerol, 8 µl of saturated bromophenol blue and 10 µl of IO mg/ml ethidium bromide. The 
RNA samples were electrophoresed at 80-100 V for 2 hr in I X MOPS as running buffer and 
detected by UV light. For Northern blotting 20 µg of total RNA was denatured and subjected 
to electrophoresis on denaturing 1 % formaldehyde containing agarose gels. No ethidium 
bromide was added to the loading dye for preparative gels. RNA samples were electrophoresed 
at 80 V for 2 hr. 
18.2. Mono-directional transfer 
A glass dish was filled with approximately I litre of 20 X SSC (3 M NaCl, 0.3 M sodium 
citrate, pH 7.0), covered with a glass plate followed by 3 sheets of Whatman 3 MM paper 
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soaked in 20 X SSC to form a wick. The gel was placed on the Whatman paper and Hybond-N+ 
membrane (Amersham) was layered on top followed by 3 sheets of Whatman 3 MM paper 
soaked in 20 X SSC. The area around the gel was covered with cling wrap. A stack of paper 
towels (approximately 5 cm thick) was placed on top of the membrane, followed by another 
glass plate and a mass of 0.5 kg. The RNA was allowed to transfer overnight and then fixed to 
the membrane by UV-crosslinking (Hoefer). To check the efficiency of transfer of the RNA 
from the gel to the membrane, membranes were stained with methylene blue after mono-
directional transfer as follows; soaked the m~mbrane in 5% acetic acid for 15 min at room 
temperature. Thereafter the membrane was transferred to a solution of 0.5 M sodium acetate 
(pH 5.2) and 0.04% methylene blue for 10 min at room temperature. The membrane was rinsed 
in H20 for 10 min. 
18.3. Hybridisation 
Northern blot analysis was performed under conditions of high stringency. After UV-
crosslinking the membrane was prehybridised in 2 X PIPES, 0.5% (w/v) SDS, 50% (v/v) 
formamide and 20 µg/ml of denatured herring sperm DNA for 2-4 hr at 42°C. The volume of 
prehybridisation solution needed was calculated according to the formula in Sambrook et al. 
( 1989) where O .2 ml of solution is required per cm
2 of membrane. Thereafter the labelled probe 
(section 14.2 and 14.3) was denatured by boiling for 5 min and added to the prehybridisation 
solution. Hybridisation was allowed to proceed overnight, at 42°C, with shaking. After 
hybridisation, the membrane was washed twice in 200 ml of 2 X SSPE (0.3 M NaCl, 18 mM 
NaH2P04, 2 mM EDTA, pH 7.4), 0.1% (w/v) SDS at room temperature for 10 min, followed 
by 1 X SSPE, 0.1% (w/v) SDS for 15 min at 65°C, and finally in 0.1 X SSPE, 0.1% (w/v) SDS 
for 10 min at 65°C. The final wash was repeated 1-3 times depending on the amount of 
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radioactivity on the membrane. All washes were performed with shaking. The membrane was 
dried between two pieces of Whatman 3MM paper, wrapped in Saran wrap and signals detected 
by autoradiography. Membranes were stripped by placing in boiling 0.5% (w/v) SDS. The 
solution was allowed to cool to room temperature. The success of stripping was checked by 
autoradiography. 
19. Cell culture 
aT3-1 , aT4, GH3 and GTI-7 cells were maintained in Dulbecco' s modified Eagle' s medium 
(DMEM, Gibco ), supplemented with 4500 mg glucose/litre, while COS-I cells were grown in 
DMEM, supplemented with 1000 mg glucose/litre. Antibiotics (streptomycin (100 µg/ml) and 
penicillin (100 U/ml)) and fetal calf serum, to a final concentration of 10%, (FCS, Highveld 
laboratories)) were added to the media. Cells were grown in 75 cm2 or 150 cm2 flasks and 
incubated at 37°C in 5% CO2 . GTI-7 cells were grown in 75 cm
2 tissue culture flasks coated 
with 15 µg/ml polyornithine. Media was changed every 48 hrs. aT3-1 cells were passaged by 
removing media, adding 3 ml of Buffer I (140 mM NaCl, 4 mM KCl, 20 mM HEPES, 1 mg/ml 
BSA, 8.3 mM glucose, 1 mM EDTA, pH 7.4) to the cell monolayer and shaking the flask 
slightly. Cells were then sucked up with a 5 ml pipette and transferred to a 15 ml centrifuge 
tube. Cells were spun down at 100 g for 5 min and the cell pellet resuspended in 5 ml of fresh 
media. 50 µl of cells was mixed with 50 µl of trypan blue and the mixture was transferred to a 
hemicytometer and counted under a microscope. Cells were seeded into 75 cm2 tissue culture 
flasks at a density of 1.0 X 106 and 10 ml of fresh media added. COS-I , aT4, GH3 and GTl-7 
cells were split with trypsin (5 mM EDTA, 1.37 M NaCl, 27 mM KCl, 81 mM Na2HP04, 14.7 
mM KH2P04, 11.1 mM glucose and 1.25% trypsin (BDH Biochemical) for COS-I , aT4 and 
GH3 cells, while 2.5% trypsin was used for GTl-7 cells, pH 7.2). Media were removed from 
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cells, 3 ml of trypsin added, and cells incubated at 3 7°C for 5 min. After cells had dislodged 
from the flasks, they were sucked up with a 5 ml pipette and transferred to 15 ml centrifuge 
tubes. Cells were counted as before and seeded into 75 cm
2 or 150 cm2 tissue culture flasks. 
19.1. Transfections 
19.1.1. Transfection of aTJ-1 cells 
19.1.1.1. Transfection using the calcium phosphate method 
Cells were seeded at a density of 2 X 106 into 60 mm plastic petri dishes, containing 5ml of 
DMEM-10% FCS. After 24 hr, subconfluent cells (approximately 80%) were transfected with 
the various constructs by the calcium phosphate method as described previously ( Ausubel et al. 
1987; Christine Ferguson, personal communication). Variable amounts of luciferase constructs, 
~-galactosidase expression vector and SF-1 cDNA were transfected. DNA, dissolved in TE 
buffer, was added to 31 µl of 2 M CaCh to make up a total volume of 250 µl and then slowly 
added (with agitation) to 250 µ1 ofHEPES buffer (274 mM NaCl, 42 mM HEPES, pH 7.1) and 
5 µl of 100 X P04 solution (70 mM Na2HP04, 70 mM Na2H2P04, pH 7.0). A precipitate was 
allowed to form by leaving at room temperature for 30 min. During this incubation media was 
removed from the cells to be transfected and the cells washed with 5 ml of HEPES-buffered 
Dulbecco' s modified Eagle's medium (HEPES-buffered DMEM). The precipitate formed (0.5 
ml) was resuspended well and then added to the subconfluent cell monolayers in the petri 
dishes. Cells were incubated at 37°C in 5% CO2 with the calcium phosphate-DNA precipitates 
for 24 hr. After 24 hr, the media was replaced with fresh media and tranfectants were harvested 
after 24 hr. 
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19.1.1.2. Transfection using lipofectin and lipofectamine 
aT3-l cells were transfected with lipofectin® reagent (Life Technologies). The method 
described by the manufacturers was followed. Cells were seeded into 60mm petri dishes at a 
density of2.5-5.0 X 106. DNA (2 µg) was mixed with 250 µl ofOPTIMEM (Gibco). The DNA 
to be transfected was made up of 1.56 µg of pGL2-control and 0.44 µg of J3-galactosidase 
vector. In a separate tube 250 µl of OPTIMEM was mixed with IO µl of I mg/ml lipofectin. 
The two solutions were mixed and left at room temperature for 15 min. During this incubation 
media were removed from cells and they were washed with 5 ml of HEPES-buffered DMEM. 
Mixtures were diluted by adding 2 ml of OPTIMEM and then added to the cells ( 40-60% 
confluent, approximately 24 hr after seeding) plated in 60 mm petri dishes. Cells were incubated 
with the lipofectin-DNA complexes for 5.5 to 6 hr at 37°C in 5% CO2. After the 5.5 to 6 hr 
incubation, 2.5 ml ofDMEM-20% FCS was added to the cells and incubated overnight at 37°C 
in 5% CO2. After 24 hr the media was replaced with 5 ml of DMEM-10% FCS and incubated 
for a further 24 hr. Cells were harvested 48 hr after transfection. 
19.1.1.3. Transfection using electroporation 
aT3-l cells were transfected by electroporation usmg the method described by the 
manufacturers (Invitrogen, Electroporater II). Cells (2.6 X 10
6 per 500 µl) were added to 0.4 
cm cuvettes containing 12.58 µg of pGL2-control vector and 4 µg of J3-galactosidase vector. 
The cells were mixed with the DNA by gently tapping the cuvettes and then incubated on ice for 
IO min. During this incubation the electroporator was charged, after which the cells were 
electroporated. The settings used were 330 V, 500 µF capacitance and - resistance. After 
electroporation samples were placed on ice for IO min, I ml of pre-warmed DMEM-high 
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glucose media added, and then transferred to 100 mm petri dishes containing 9 ml of DMEM-
high glucose media. Cells were harvested 48 hr after transfection. 
19.1.2. Transfection of COS-1 and GH3 cells 
19.1.2.1. Transfection using lipofectin 
COS-I and GH3 cells were transfected usmg lipofectin® reagent (Life Technologies), as 
described for aT3-1 cells. Cells were seeded into 60 mm petri dishes at a density of 2.5-5 X 
105. For COS-I cells, petri dishes were coated with poly-D-lysine. Briefly, DNA to be 
transfected was mixed with 250 µl of OPTIMEM. In a separate tube 250 µl of OPTIMEM was 
mixed with 10 µI of 1 mg/ml lipofectin. The same procedure was followed as for aT3-1 cells 
and transfectants were harvested 48 hr after transfection. 
19.1.2.2. Transfection of COS-1 cells using DEAE-Dextran 
COS- I cells were seeded into I 00 mm petri dishes, coated with poly-D-lysine, at a density of 
3.0 X 106. Cells were grown until 80% confluent, then washed with 10 ml of HEPES-buffered 
DMEM. 4 ml of DNA/HBS/DEAE-Dextran mixture was added to the cells. The 
DNA/HBS/DEAE-Dextran mixture was made up as follows: 13 .5 µg of pGL-2 control and 
5 .25 µg of 13-galactosidase vector, and 4 ml of 3 mg/ml HBS/DEAE-Dextran diluted I 0-fold in 
DMEM media. Cells were incubated with this mixture for 4 hr at 37°C and 5% CO2. After 4 hr, 
media was aspirated off and 10 ml of 200 µM chloroquin/DMEM/2% FCS was added to the 
cells. The cells were incubated for a further 50 min and then washed with 10 ml of serum-free 
DMEM. 10 ml ofDMEM/10% FCS media was added to the cells and the cells returned to the 
incubator. Cell were harvested for assays 48 hr after transfection. 
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19.1.2.3 Transfection of COS-1 cells using electroporation 
COS-1 cells were transfected by electroporation using the protocol described for aT3-1 cells 
(19.1. 1.3). 
19.2. Harvesting cell extracts 
Cells were washed twice with 5 ml of PBS, after which 400 µl of 1 X Reporter Lysis Buffer 
(RLB, Luciferase Assay kit, Promega) was added per 60 mm petri dish and the solution left at 
room temperature for 15 min. Cells were scraped from the dish, with a rubber policeman, and 
the cell lysate was transferred to a microfuge tube on ice. The lysate was vortexed for 15 sec, 
then centrifuged for 2 min at 4 °C in a microfuge. The supernatant was stored in aliquots at -
10°c . 
19.3. Protein Determination 
Protein concentrations were determined usmg the BIORAD assay reagent from Bio-Rad 
Laboratories, which is based on the method of Bradford (1976). Bovine serum albumin (BSA), 
concentrations ranging from 0-25 µg were used as standards. Briefly, 1 ml of 1 X BIORAD was 
added to standards and samples made up to 50 µl with H20 or RLB, and left at room 
temperature for 5 min before taking the OD595 . The volume of cell extract used per assay varied 
from 2-10 µl, depending on the cell type transfected but generally 5 µl of cell extract was used 
for aT3-1 and GH3 cells while 2 µl was used for COS-I cells. 
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19.4. f3-galactosidase (f3-gal) assays 
f3-gal activity was measured by adding buffer Z (60 mM Na2HP04, 40 mM NaH2P04.2H20, 10 
mM KCl, 1 mM MgCh.6H20 , 50 mM f3-mercaptoethanol, pH 7.0) to the cell extract, in RLB, 
to a final volume of 200 µI. The amounts of cell extract and buffer Z used varied for different 
assays, but generally 40 µl of cell extract was added to 160 µl of buffer Z for a. T3-1 and GH3 
cells, while only 5 µl of cell extract was used for COS- I cells. The reaction was started by 
adding 40 µl of 4 mg/ml ONPG (O-nitrophenyl-f3-D-galactopyranoside dissolved in solution 2 
(60 mM Na2HP04, 40 mM NaH2P04, pH 7.0) and incubated at 30°C until a yellow colour 
developed. The reaction was stopped by adding 100 µl of 1 M Na2C03 and the OD420 measured. 
f3-galactosidase activity was expressed as: 
A. l · · OD420/hr/ p-ga actlVIty= mg protein (b) 
(Herbomel et al. 1984). 
19.5. Luciferase assays 
Luciferase assays were performed as described in the Luciferase assay kit manual (Promega). 
Generally 20 µl of cell extract, in RLB, was added to 100 µl of luciferase assay substrate and 
the amount of luciferase produced was measured in a luminometer (1253-003 Lurninometer, 
BioOrbit). 350 µl of Tris-acetate buffer (0.1 M Tris, 2 mM EDTA, pH 7.75 with acetic acid) 
and 100 µl of substrate were added to the cuvette, vortexed, and a background reading taken. 
Luciferase units was determined by adding 20 µ1 of cell extract to the cuvette, vortexing, and 
measuring light production 30 sec after adding the cell extract to the substrate. Luciferase units 
was expressed as: 
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l · c. · _ luciferase produced/ uc11erase uruts - mg protein (a) 
Normalised luciferase activity was determined by dividing luciferase units produced by B-gal 
activity (3/b) to correct for transfection efficiency. 
20. Computer analysis 
Sequencing analysis was performed using the GCG program on the University of Cape Town 
VAX. Sequences were compared using Bestfit, while restriction enzyme maps were determined 
using Map or Mapsort. B-gal and luciferase results were graphically analysed using GraphPad 
PRISMTM version 1. 03 computer software by GraphPad Software Incorporation. Standard 
errors were calculated by the GraphPad PRISM program. 
CHAPTER3 
RESULTS 
1. Partial sequence analysis of the mouse GnRH receptor gene 
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A mouse GnRH receptor genomic clone, clone ID, containing 500 bp of 5'
 -flank, 569 bp of 
coding region and 38 bp of intergenic region, was obtained from Stuart Sealf
on at Mt. Sinai in 
New York. Clone ID was partially sequenced to ascertain if the correct clone 
was obtained, and 
also to determine its percentage homology with the sequence of the 5' -flank
ing region of the 
mouse GnRH receptor gene, published by Albarracin et al. (1994) (Fig. 3 .1 ).
 Partial sequence 
analysis of clone ID was obtained by sequencing it with various primers. The
 primers used are 
listed in section 2.4. DNA sequence analysis was performed using the 
GCG sequencing 
program. Partial sequence analysis of clone III revealed 100% DNA ho
mology with the 
sequence published by Albarracin et al. (1994). 
-1164 CCCACATCTT GCTGTAATGG GCTTTCTGCT GTACCCAACA G
TGTATTTTG 
-1114 AACTTATCTT GATTTCTTCA TATAGTAAAA CTATAAAACT T
CTCAAAATT 
-1064 GCTTTATTAC CAGCAAAGAC TAGGAGAGTG TGTGTAGTAG A
GACTCAGTA 
-1014 ACTCACTACT AAATAAATTA ATAGCATACA GTATAAAAAG A
ATAAACCAA 
-964 CAAAAATACA CCATCCAAAC CAAAATAGCT GCCTTTACCC T
AATAGTGTC 
-914 CCTGCTTTGG GTGGGTGTGA TGAAAGCAAA GTAATTGGTA A
TCTGATAAC 
-864 AACAAACTGT GACTTACTAA ATTCCAATGG AAGTCATACC A
ATATTTGTA 
-814 TGGCTAAATA CTATCATCAC ATAACACAGA GAAGGATTCT A
AGTAGCCTC 
-764 AATGTGGGGT GGTTATATAA CACAATAGGA TTATAAATTA TAA
ATTAGCA 
-714 TATTATATCA TCAATTCAGT TCCAGGATTT ATGCAAGTAT GTA
GTTTTGT 
-664 TCCAGTATCT AGTTTTCCTT TCAATTTGGT ATGATAATAA CAAGTA
AAAT 
-614 ATTTACCCAA TTATAAAATC AAGGCAATAA CAAAAATAAT TTTA
CTATAA 
-564 TTTCAGCATG GATAGTCTGA TCATTAAAAC CAATTGATAA ACTTAA
ATCT 
-514 AGAATAATTG GTATTAGAAC AGGCTGCTTA AAACAGTTAA AGTACTAG
CT 
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-464 ATAAGTCCGT CGTGTGACTA TTCAGCAAAA TGCATTTGAA AAGCAATTGT 
-414 TTTGAGAAGT ATGGTCTTCA AACAACAGAT TTTAAATTGG ATCGGGATTT 
-364 TTAAATTACT TTTCTGTATT TCATTTTGTA TCTGTCTAGT CACAACAGTT 
-314 TTTAGAAAAC CTATTCATTA AGGCTAATTG GATGATATTA TGAGTCACTT 
-264 TCGACATCAG AATTAGACTC CAAGTGTCCT TCCTCACCTA CGATAAAAAG 
-214 ACGGGCCATC TGCTGAGGGG CTACGGTTAC ACTTGGCCTT CAGGAGGGCT 
-164 TGGCATGTTC TGTTAGCACT CTTTTAGATT ATAAACCGAA AAACAAGTTT 
-114 ACCTTGATCT TTCACGTTAA GTCCAGAGTA TCTTGGGAAA AATAAATTAG 
-64 GCAGAAATGC TAACCTGTGA CGTTTCCATC TAAAGGAGGC AGACATCAAC 
,} 
-14 AGCGCTTCGC GTTCAGTTAT GATAAAACAT CAGAAGTAAC AGGGACTCCA 
+37 CTCTTGAAGC cjGTCCTTGb AGAAAT~ CTAACAATGC ATCTCTTGAG 
+87 CAGGACCCAA ATCACTGCTC GGCCATCAAC AACAGCATCC CCTTGATACA 
Figure 3.1 . Nucleotide sequence of the 5'-flanking region of the mouse GnRH receptor gene 
(Albarracin et al. 1994). The position of the major transcription start site which is located 63 bp 
upstream of the translational start site is indicated by an arrowhead. The putative GSE element 
and the translation start site (ATG) are boxed. Nucleotide sequences obtained by sequencing 
clone III are underlined. 
2. cxT3-1 and cxT4 cells contain a GSE/SF-1 binding nuclear protein(s) 
Protein-DNA binding studies were performed using nuclear extracts prepared from cxT3-1, cxT4 
and GT 1-7 cells. Oligonucleotides corresponding to the mouse GnRH receptor 'GSE' 
(oligonucleotide GSE in the materials and methods section) and to a strong SF-1 binding site 
(oligonucleotide SF-1) found in the promoter of the aromatase gene were end-labelled and used 
as probes in gel mobility shift assays. A nuclear factor-DNA complex is seen in both cxT3-1 and 
cxT4 cells (Fig. 3.2). A second shifted complex is seen in cxT3-1 cells. This is consistent with 
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findings of others who have identified a protein-DNA complex with similar mobility to the upper 
complex as SF-1 binding to its DNA-binding element, whereas a protein-DNA complex with 
similar mobility to the lower complex correlates to the binding of an SF-1 degradation product 
(Barnhart and Mellon, 1994; Lala et al. 1992). No similar binding complex is seen in GTl-7 
cells (Fig. 3.2). The finding that a complex with indistinguishable mobility was observed when 
both the GSE and SF-I oligonucleotides were used as radiolabelled probes, suggested that SF-1 
is the protein in a.T3-1 and a.T4 cells that binds the putative mouse GnRH receptor GSE. Since 
it is known that a.T4 cells do not express GnRHR (section 4), the presence and binding of SF-1 
to the GSE in a.T4 cells is not sufficient for GnRHR expression. 
Cell line GTl-7 a.TJ-1 a.T4 
I I I I 
Probe GSE GSE SF-1 SF-1 GSE GSE SF-1 SF-1 GSE GSE 
Lane 1 2 3 4 5 6 7 8 9 10 




Figure 3.2. aT3-1 and aT4 cells contain a GSE/SF-1 binding nuclear protein(s). 
Oligonucleotides corresponding to the 'GSE' of the mouse GnRH receptor gene (lanes 1, 2, 5, 
6, 9, 10) or an SF-1 binding site (lanes 3, 4, 7, 8) were used as radiolabelled probes. These 
probes were incubated with 5 µl of nuclear extracts prepared from aT3-1 (lanes 4, 5), aT4 
(lanes 6, 8, 10) or GT 1-7 cells (lanes 2, 3) and subjected to electrophoresis in a gel mobility shift 
assay. Band 1 represents the major shifted band obseved in both aT3-1 and aT4 cells. Band 2 
( observed with aT3-1 nuclear extracts) is most likely the binding of a SF-1 degradation product 
to the GSE and SF-1 radiolabelled probes. Lanes 1, 7 and 9 represent mobility shift assays 
without adding nuclear extracts to the reactions. These are the results of several experiments. 
Results in Fig. 3.2 have suggested that SF-1 is the protein in aT3-1 and aT4 cells that bind the 
GSE and SF-1 oligonucleotides. To further verify the sequence specificity of the DNA-protein 
interactions, gel mobility shift assays were performed with nuclear extracts prepared from aT3- l 
cells, using the GSE, SF-1 and mutated GSE (mGSE) oligonucleotides as unlabelled 
competitors together with the GSE and SF-1 oligonucleotides as radiolabelled probes. 
Investigators have found that a 2 bp nucleotide mutation (CC=> TT) in the GSE completely 
abolishes binding of SF-1 (Hom et al. 1992) or diminishes but does not abolish binding of SF-1 
(Wilson et al.1993). This 2 bp nucleotide change (CC::::>TT) was incorporated into the putative 
mouse GnRH receptor GSE used in this study to generate a binding site with a theoretically 
diminished affinity for SF-1 (mGSE oligonucleotide in materials and methods). Figs. 3.3 and 3.4 
illustrates gel shift experiments using the mutated GSE, the GSE and SF-1 oligonucleotides as 
unlabelled competitors together with either the GSE or SF-1 oligonucleotides as radiolabelled 
probes. The major shifted band seen when using the wild type GSE (Fig. 3.3A) and SF-1 (Fig. 
3.3B) oligonucleotides as probes is completely abolished when challenged with a 100-fold 
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excess of cold GSE or SF-I oligonucleotide competitors. There is substantial but incomplete 
competition of the mGSE oligonucleotide with the GSE and SF-1 radio labelled probes, implying 
that the 2 bp change which has been incorporated into the 'GSE' only diminishes binding of SF-
1, but is not sufficient to completely abolish binding (Fig. 3.3A, lane 1). These results show that 
the interaction between SF-I and the 'GSE' sequence from the GnRH receptor gene is not 
highly sequence specific as SF- I is still able to recognise the GSE with a 2 bp mutation. In 
contrast, when SF-I is used as the probe (Fig. 3.3B), the mutated GSE shows virtually no 
competition (Fig. 3.3B, lane 5). The results show that while the protein(s) in the nuclear extract 
binds to both the GSE and SF-I sites, it has higher affinity for the SF-I site than the GSE and 
appears to have some affinity for the mutated GSE. 
Probe GSE 
Competitor mGSE SF-1 GSE 











GSE SF-1 mGSE 
3 4 5 
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Figure 3.3. Mutations in the GSE and SF-1 sites affect SF-1 binding. Mobility shift assays 
using nuclear extracts prepared from aT3-l cells (5 µl) were performed using the GSE and SF-1 
oligonucleotides as radiolabelled probes and the GSE, SF-1 and mutated GSE oligonucleotides 
as unlabelled competitors. Competition assays were performed using unlabelled oligonucleotides 
at a 100-fold molar excess to radiolabelled probes. Figure 3.3A is the mobility shift assay using 1 
ng of the GSE oligonucleotide as probe and contain the following oligonucleotides as 
competitors: lane 4, no competitor; lane 3, GSE; lane 2, SF-1; lane 1, mGSE. Lane 5 is a 
mobility shift reaction using the GSE oligonucleotide as probe without adding nuclear extract. 
Figure 3 .3B is the mobility shift assay using 1 ng of the SF-1 oligonucleotide as probe and 
contain the following oligonucleotides as competitors: lane 2, no competitor; lane 3, GSE; lane 
4, SF-1; lane 5, mGSE. Lane 1 is a mobility shift reaction using the SF-1 oligonucleotide as 
probe without adding nuclear extract. Band 1 represents the major DNA-protein complex 
formed. Band 2 most likely correlates to the binding of a SF-1 degradation product to the GSE 
and SF-1 oligonucleotides. 
3. A SF-1-like protein binds to the mouse GnRH receptor 'GSE' 
A 378 bp FokI fragment, encompassing the region -270 bp to +108 bp relative to the 
transcription start site (Fig. 3 .1 ), containing the putative mouse GnRH receptor 'GSE' was 
excised from clone III, by restriction enzyme digestion, and used in DNase I footprinting 
experiments with nuclear extracts prepared from aT3- l cells. Two different concentrations of 
nuclear extracts were used in the footprinting experiment. To test the sequence specificity of the 
DNA-protein interaction unlabelled GSE and mGSE oligonucleotides were used as competitors 
in the footprinting experiment. A footprint is seen over the 'GSE' which is competed away with 
the cold wild type GSE oligonucleotide but not with the mutated GSE oligonucleotide (Fig. 
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3.4). These results show that a nuclear protein(s), present in aT3-1 cells, binds over the mouse 
GnRHR 'GSE' and that this protein-DNA interaction is sequence specific, as the mGSE 
oligonucleotide fails to compete for binding. Mobility shift assays have provided strong evidence 
that the nuclear protein(s) in aT3-l cells that bind the mouse GnRH receptor 'GSE' is SF-1. No 
other footprints could be detected in this region (Fig. 3.4). Our studies indicate that the major 
protein-DNA interaction over this region occur over the 'GSE' . 








Figure 3.4. SF-1 binds over the mouse GnRH receptor 'GSE' . DNase I footprint anal
ysis of 
aT3-l nuclear proteins binding to the mouse GnRH receptor promoter. The 
32P-end-labelled 
378 bp fragment of the mouse GnRH receptor gene (1 ng), containing the putative 
GSE site, 
was incubated with 6 µl (lanes 4, 5, 7, 8, 10, 11) and 10 µl (lanes 6, 9, 12) ofaT3
-l nuclear 
extract partially digested with DNase I, and separated on a 6% polyacrylamide gel 
as described 
in the materials and methods. A 100-fold molar excess of the unlabelled GSE (lanes 1
0, 11, 12) 
and the mutated GSE oliginucleotides (lanes 7, 8, 9) were used as competitors. T
he protected 
region is indicated by the bracket. The fact that the faint footprint occurs over the G
nRHR GSE 
is verified by competition experiments with the mutated and wt GSE oligonuc
leotides. No 
footprint is seen when competed with the wt GSE oligonucleotide (lanes 10, 
11 , 12). A 
footprint is seen when competed with the mutant GSE oligonucleotide (lanes 7, 8,
 9). pBR322 
digested with Hpall (radiolabelled by the Kienow method as discussed in the m
aterials and 
methods section 14.1) is used as a molecular size marker (lane 1). DNasel footprint
ing reactions 
using the labelled Fokl fragment as probe without adding nuclear extract is shown 
in lanes 2, 3, 
13, 14. 
4. GnRH receptor expression is not solely dependent on SF-1 RNA expression 
Using three different cell lines, the possible correlation between SF-1 RNA ex
pression and 
GnRH receptor RNA expression was investigated. aT3-l cells are transforme
d precursor 
gonadotrope cell lines which have been previously shown to express GnRHR RN
A and SF-1 
RNA (Windle et al. 1990, Barnhart and Mellon, 1994). aT4 cells are also tr
ansformed 
gonadotrope cells, but they have been shown not to express GnRHR RNA. It is
 not known 
whether they express SF-1 RNA. GTl-7 cells are transformed neuronal cells and it i
s not clear if 
they express GnRHR or SF-1 RNA (Mellon et al.1990, Barnhart and Mellon, 1994).
 Northern 
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blot analysis was performed on RNA extracted from aT3-I , aT4 and GT1-7 cells, using SF-I 
or mouse GnRH receptor cDNA as probes. As seen in Fig. 3.5A, SF-1 message was detected in 
aT3-1 and aT4 cells, but was absent from GTI-7 hypothalamic neurons. When the intensity of 
the SF-I signals seen in aT3-l and aT4 were quantified with an IMAGER (Instant Imager, 
Packard) and standardised against P-actin values (Fig. 3.5C) we found the signal in aT4 cells 
0.5 times less than that seen in aT3-I cells. The same blot was stripped and probed with the 
mouse GnRH receptor cDNA. The GnRH receptor is expressed in aT3-l cells but not in aT4 
and GTl-7 cells (Fig. 3.5B). These results show that GnRH receptor gene expression is not 











a.T4 a.TJ-1 GTl-7 
1 2 3 
P-actin 
a.T4 a.TJ-1 GTl-7 
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Figure 3.5. SF-1 mRNA is expressed in both aT3-1 and aT4 cells, while GnRH receptor 
mRNA is only expressed in aT3-1 cells. RNA samples from aT3-l (lane 2), aT4 (lane l)and 
GTl-7 (lane 3) were subjected to Northern blot analysis using either SF-1 cDNA (A), GnRH 
receptor cDNA (B) or ~-actin (C) as probes. A single band of 2.9 kb is seen in aT4 and aT3-1 
cells when probed with SF-1 cDNA (A; lanes 1 and 2, respectively). Two transcripts (a major 
one of 4.5 kb and a minor one of 1.8 kb) are seen in aT3-1 cells when this blot is probed with 
GnRHR cDNA (B; lane 2). aT4 cells do not express GnRH receptor RNA (B; lane 1). GTl-7 
cells do not express SF-1 or GnRH receptor RNA (A and B; lane 3). The blob in Fig. 3.5A is an 
artifact which might erroneously suggest that a band representing SF-1 RNA is present in GTl-7 
cells. 
5. Preparation of constructs containing 563 hp of the GnRH receptor gene linked to a 
luciferase reporter gene for functional assays. 
To evaluate the functionality of the 563 bp fragment of the mouse GnRH receptor gene (-500 to 
+63 relative to the transcription start site), luciferase assays were performed. Before cloning the 
GnRHR fragment into the pGL2-basic vector, the ATG, at +63 bp relative to the transcription 
start site, of the mouse GnRH receptor gene was mutated. The translation start site was mutated 
for two reasons, firstly to ensure that translation starts at the reporter gene and that it does not 
start at the ATG of the GnRH receptor gene as this may result in out of frame translation of the 
luciferase reporter gene and therefore in the luciferase protein not being expressed. The second 
reason for mutating the ATG was to generate a BglII site to facilitate cloning into the pGL2-
basic vector. The restriction site was generated using oligonucleotide 1 S ( section 2 .4) and 
employing Kunkel's method, as described earlier (Fig. 3.6). A 580 bp Bamlil-BglII fragment 
(563 bp of GnRHR gene sequence and 17 bp of pBluescript®SK phagemid sequence) was 
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excised from clone ill and cloned into the BglII site of the promoterless luciferase vector, 
pGL2-basic, to form wt GnRHR-LUC (Fig. 3.7). The mut GnRHR-LUC construct was formed 
by fusing the same 563 bp fragment, but with a CC=> TT mutation in the 'GSE' at position +48 
bp relative to the transcription start site (site-directed mutagenesis using oligonucleotide 2S) to 
the pGL2-basic vector (Figs. 3.6 and 3.7). Recombinants were screened by miniprep plasmid 
DNA isolation, restriction enzyme digestion and DNA sequencing with the luciferase primers, 
GLl and GL2. Recombinants with the GnRH receptor fragment cloned in the sense direction, 
i.e. driving expression of the luciferase gene, were selected. Gene expression studies were 
performed by transfection of these constructs into mouse gonadotrope (a.T3-1), mouse 
somatotrope (GH3) and monkey kidney (COS-1) cells, followed by measurement of luciferase 
activity in cell lysates. The promoterless vector, pGL2-basic, was transfected serving as a 
control for basal levels of luciferase expression. The pGL2-control vector, which contains a 
strong SV40 promoter was used as an internal standard for measuring luciferase activity. 
Transfection efficiency was determined by transfection with the J3-galactosidase vector, 
pCISLACZ. 
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~+41 hp 
~+66 hp 
Figure 3.6. The ATG of the mouse GnRH receptor gene was mutated to a BglII site to facilitate 
cloning into the pGL2-basic vector. The 'GSE' element was mutated to test the functionality of 
this element. The first arrow shows the 2 bp nucleotide change (CC~TT) in the 'GSE', while 
the second arrow shows the mutation of the ATG to a BglII site. The sequencing gel autorad of 
the region covering +41 to +66 hp relative to the transcription start site (Fig. 3 .1) is shown. The 
mutant sequence is shown i.e. TGAAGCCTGTTTTTGGAGAAAGATCTCTAA, where the 
mutated sequences are shown in bold. The wild type sequence of the GnRHR 563 bp fragment is 
TGAAGCCTGTCCTTGGAGAAAIATGGCTAA, where the bases mutated in the mutant 
sequence are underlined. 
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Figure 3. 7. wt GnRHR-LUC and mut GnRHR-LUC contain 563 bp of wild type mouse 
GnRHR gene sequence and 563 bp of mutated GnRHR gene sequence, respectively, linked to 
the luciferase gene in the reporter plasmid pGL2-basic. After site-directed mutagenesis, as 
described in text, the 580 bp fragment (563 bp of GnRHR gene sequence and 17 bp of 
pBluescript®SK phagemid sequence) was excised from clone III and cloned into the BglII site 
of the pGL2-basic vector. Recombinants with the GnRH receptor gene sequence cloned in the 
sense direction were selected for and used in gene expression studies. 
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5.1. Optimising the luciferase assay 
5.1.1. Determination of the linear range of light detection 
The linear range of luciferase detection was determined by making serial dilutions of purified 
luciferase enzyme (Boehringer Mannheim) and measuring luciferase activity in a luminometer. 
Table 3 .1 illustrates luciferase units obtained for different concentrations of purified luciferase 
enzyme. The linear range of light detection was obtained by using between 1 pg/µl and 10 µg/µl 
of purified luciferase enzyme. 
Table 3.1. Determining the concentration ofluciferase which produces linear light 
production. 
Concentration of luciferase Luciferase units 
10 µg/µl 1294 
1.0 µg/µ1 99.00 
0.1 µg/µl 12.00 
0.01 µg/µl 4.000 
1.0 ng/µl 0.450 
0.1 ng/µl 0.042 
0.01 ng/µl 0.005 
1.0 pg/µl 0.001 
0.1 pg/µl 0.000 
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Figure. 3.8. The log of luciferase units produced is plotted against the concentration of purified 
luciferase enzyme. Numbers 1, 2, 3, 4, 5, 6, 7, 8 and 9 represents 0.1 pg/µl, 1.0 pg/µl, 0.01 
ng/µl, 0.1 ng/µl, 1.0 ng/µl, 0.01 µg/µl, 0.1 µg/µl, 1.0 µg/µl and 10 µg/µl, respectively. Light 
production is linear for the concentrations of purified luciferase enzyme ranging from 1 pg/µl to 
10 µg/µl. Lyophilised luciferase enzyme (Boehringer Mannheim) was dissolved to a final 
concentration of 1 mg/ml in 0.5 M of ice-cold Tris-acetate buffer (pH 7.5). Serial dilutions 
(Table 3.1) were made using 1 X Reporter Lysis Buffer (Luciferase Assay Kit), and luciferase 
activity measured in a luminometer, 10 seconds after starting the reaction. 
5.1.2. Determination of the optimal time for luciferase detection 
Luciferase assays were optimised by taking sample readings at various time points to determine 
during which time frame light emittance is constant and fluctuation of luciferase activity is at a 
minimum. Luciferase activity decreased by between 10% and 30% after 300 seconds, but was 
fairly constant between 5 and 60 seconds (Table 3.2). As a consequence, luciferase readings 
69 
were always measured 30 seconds after adding our cell extracts to the substrate and thereby 
starting the light production. 
Table 3.2. Optimising the luciferase assay by determining the decay rate ofluciferase 
production. Readings were taken at various time points between 5 and 300 seconds after 
starting the reaction. Numbers 1 to 10 are the results of 10 independent assays. 
TIME IN SECONDS 
No. 5 30 60 90 120 150 180 210 240 270 
1 4.95 4.99 4.99 4.97 4.86 4.78 4.69 4.59 4.52 4.50 
2 5.69 5.63 5.59 5.54 5.55 5.50 5.43 5.36 5.30 5.24 
3 0.17 0.17 0.16 0.16 0.16 0.16 0.15 0.16 0.15 0.14 
4 0.06 0.06 0.06 0.06 0.05 0.05 0.05 0.05 0.05 0.05 
5 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.10 0.10 0.10 
6 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 
7 0.08 0.07 0.07 0.07 0.07 0.07 0.07 0.06 0.06 0.07 
8 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
9 0.05 0.05 0.05 0.05 0.05 0.04 0.04 0.05 0.04 0.04 
10 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
5.1.3. Optimisation of transfection conditions 












A trial experiment comparing liposome-mediated transfection versus DEAE-Dextran 
transfection was performed to determine which method worked best, as transfection efficiencies 
are dependent on many variables such as cell lines and constructs to be transfected, DNA 
isolation methods and tissue culture conditions. Only two methods were tested for COS- I cells 
as both methods were previously shown to work for transfection of COS- I cells. After 
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transfection, results were analysed by doing ~-galactosidase and luciferase assays as described in 
the materials and methods. Liposome-mediated transfection was about 1.5 X more efficient that 
DEAE-Dextran transfection for both ~-galactosidase and luciferase activities. 
Table 3.3. Lipofectin and DEAE-Dextran transfection methods were compared for COS-
I cells. After transfection, cell extracts were harvested and used in ~-galactosidase and 
luciferase assays. Transfection efficiency was 1. 5 X higher when using lipofectin as opposed to 
using DEAE-Dextran. 
Method of transfection f3-galactosidase units Luciferase units 
Lipofectin 0.87 71 
DEAE-Dextran 0.57 50 
5.1.3.2. Optimising transfecting aT3-1 cells with lipofectin and varying DNA 
concentrations 
Initially aT3-1 cells were transfected with lipofectin as lipofectin gave the best results for COS-
I cells. DNA concentrations were varied to increase the chances of getting high transfection 
efficiencies with these cells as others have previously reported that aT3-1 cells are finicky and 
difficult to transfect (Daniel Assefa, personal communication; Ian Wakefield, personal 
communication). After transfection cell extracts were harvested and assayed using P-
galactosidase and luciferase assays, but readings obtained were too low to analyse the data and 
it could therefore be concluded that liposome-mediated transfection did not work for aT3-1 
cells under the conditions used. These results emphasize the well established fact that the 
efficiency of transfection method is dependent on the cell line being transfected. 
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5.1.3.3. Transfecting aT3-1 cells by electroporation 
To try and overcome the problems in trying to transfect aT3-1 cells, transfection of aT3-1 by 
electroporation was attempted. Many studies have been performed comparing electroporation to 
other transfection methods and in the majority of cases electroporation was always the most 
successful (Paulsen et al. 1995; Spencer, 1993). This method was not successful for transfecting 
aT3-1 cells as transfectants died before they could be harvested. This may indicate that 
transfection by electroporation is too harsh for aT3-1 cells or that maybe the voltage we used 
was too high, as electroporation of COS-1 cells, which served as controls, yielded positive 
results. 
5.1.3.4. Transfecting aT3-1 cells using the calcium phosphate method. 
aT3-1 cells were transfected by the calcium phosphate method as described in the materials and 
methods. The success of calcium phosphate transfection is dependent on the quality of the DNA 
to be transfected. Supercoiled DNA is more efficiently transfected than linear or nicked DNA 
DNA used for calcium phosphate transfections was purified by caesium chloride gradient 
centrifugation as described before. The ratio of luciferase vector to f3-galactosidase vector was 
varied in transfection experiments. The necessity to include carrier DNA in transfection 
experiments was also determined. After transfection cell extracts were harvested and f3-
galactosidase and luciferase assays performed. There was no significant difference observed 
when varying the ratios of DNA transfected and therefore a luciferase vector to f3-galactosidase 
ratio of 3. 5: 1 was used. 
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Table 3.4. Transfection of aT3-l cells by calcium phosphate precipitates. The DNA 
concentrations of the reporter constructs as well as the concentration of carrier DNA is shown. 
Normalised luciferase activity was calculated by dividing luciferase units produced by B-
galactosidase units produced. 
Total pGL2-control B-gal earner ratio Normalised 
DNA(µg/µl) (µg/µl) (µg/µl) (µg/µl) luciferase act. 
8.8 5.87 2.93 2: 1 6.76±0.31 
8.8 4.1 1.17 3.52 3.5: 1:3 5.28±0.44 
8.8 6.84 1.95 3.5:1 4.49±0.15 
5.2. Lucif erase assays 
The luciferase assay system was used to a) Study promoter activity of constructs containing 563 
bp of the GnRHR gene, b) Determine whether promoter activity, if observed, was tissue-specific 
and c) Whether SF-1 played a role in promoter activity. In order to address these three issues 
wild type and mutant GnRHR-LUC constructs were transfected into aT3-1, GH3 and COS-I 
cells. SF-1 cDNA was also transfected into aT3-1 and COS-1 cells to determine the role of SF-
1 in possible promoter activity. The pGL2-control vector, containing the SV 40 promoter and 
the promoterless pGL2-basic vector were used as positive control and negative controls, 
respectively. The pCISLACZ vector served as an internal standard to monitor transfection 
effeciency. aT3-l cells were transfected using the calcium phosphate method as described in the 
materials and methods ( section 2.19 .1.1.1 ), while GH3 and COS-1 cells were transfected using 
lipofectin (2.19.1.2.1 ). 
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5.2.1. Results oftransfection of aTJ-1 cells 
Table 3.5. DNA concentrations used for calcium phosphate transfections into aT3-1 cells. !3-
galactosidase and luciferase activity was measured using the formulae given at the bottom of the 
table. Abbreviations used in table: cont, pGL2 positive control; basic, pGL2 negative control; 
wt, wt GnRHR-LUC; mut, mut GnRHR-LUC; SF-1, steroidogenic factor-I ; !3-gal, !3-
galactosidase; lucif, luciferase; rel.act., relative activity 
Concentration of DNA transfected (U!:?:) Activity measured 
Total cont basic wt mut !3-gal SF-1 !3-galb lucif alb rel.act. 
36 28 8 7.70 31 .09 4.04 1.00 
36 28 8 7.80 23 .24 3.00 0.74 
36 28 8 0.94 3.70 3.96 0.97 
36 28 8 0.87 3.45 3.96 0.97 
36 28 8 0.82 3.06 3.73 0.92 
36 28 8 0.00 0.00 0.00 0.00 
36 28 8 0.00 0.00 0.00 0.00 
36 28 8 0.00 0.00 0.00 0.00 
36 28 8 0.00 0.00 0.00 0.00 
36 28 8 0.00 0.00 0.00 0.00 
36 28 8 18.00 37.25 2.10 0.52 
36 28 8 18.10 33.42 1.85 0.46 
36 28 8 1.30 2.15 1.65 0.41 
36 28 8 1.17 2.50 2.14 0.53 
36 28 8 1.08 1.75 1.62 0.40 
36 28 8 14 4.00 20.48 5.12 1.27 
36 28 8 14 4.10 18.24 4.45 1.10 
36 28 8 14 0.49 1.40 2.86 0.71 
36 28 8 14 0.65 1.90 2.92 0.72 
36 28 8 14 0.88 1.85 2.10 0.52 
36 28 8 7.20 18.45 2.57 0.63 
36 28 8 4.90 12.86 2.62 0.65 
36 28 8 0.96 1.25 1.30 0.32 
36 28 8 1.30 2.25 1.73 0.43 
36 28 8 1.10 3.35 3.05 0.75 
36 28 8 14 3.80 19.50 5.13 1.27 
36 28 8 14 6.30 35.40 5.62 1.40 
36 28 8 14 0.57 2.35 4.12 1.02 
36 28 8 14 0.48 3.20 6.70 1.65 
36 28 8 14 0.50 2.55 5.10 1.26 
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I : c. · · luciferase units/ a= ucuerase act1V1ty = mg protein 
b A. }a "d . . OD420/hr/ = ._,-ga CtOSI ase aCtIVIty = mg protein 
alb= nomalised activity, i.e. luciferase activity per ~-galactosidase activity 
relative luciferase activity= activity relative to the pGL2-control plasmid, i.e alb for experiment 
divided by alb for pGL2 positive control plasmid 
T 
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Figure 3.9. aT3-1 cells were transiently co-transfected with the following constructs, pGL2-
control, pGL2-basic, wt GnRHR-LUC, mut GnRHR-LUC, ~-galactosidase and SF-1 cDNA as 
described earlier. DNA concentrations used for transfections are showed in Table 3.5. Numbers 
1, 2, 3, 4, 5 and 6 represents transfection with the pGL2-control, pGL2-basic, wt GnRHR-LUC, 
wt GnRHR-LUC plus SF-1 cDNA, mut GnRHR-LUC and mut GnRHR-LUC plus SF-1 cDNA, 
respectively. Each bar represents the mean ± standard error of five experiments. 
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5.2.2. Results of transfection of GH3 cells 
Table 3.4. Concentrations of DNA used for lipofectin mediated transfection and J3-galactosidase 
and luciferase activity measured in GH3 cells. Abbreviations used in table: cont, pGL2 positive 
control; basic, pGL2 negative control; wt, wt GnRHR-LUC; mut, mut GnRHR-LUC; J3-gal, J3-
galactosidase; lucif, luciferase; rel. act. , relative activity 
Concentration of DNA transfected (µg) Activity measured 
Total cont basic wt mut J3-gal J3-galb lucif alb rel.act. 
6.25 4.86 1.39 0.46 0.64 1.39 1.00 
6.25 4.86 1.39 0.77 1.04 1.34 0.96 
6.25 4.86 1.39 0.00 0.00 0.00 0.00 
6.25 4.86 1.39 0.00 0.00 0.00 0.00 
6.25 4.86 1.39 0.82 0.95 1.15 0.72 
6.25 4.86 1.39 0.27 0.48 1.80 1.30 
6.25 4.86 1.39 0.90 1.28 1.42 1.02 
6.25 4.86 1.39 0.94 1.26 1.30 0.94 
a= luciferase activity = luciferase units; mg protein 
b A a} "d · · OD420/hr/ = ..,-g actos1 ase act1V1ty = mg protein 
alb= nomalised activity, i.e. luciferase activity per J3-galactosidase activity 
relative luciferase activity= activity relative to the pGL2-control plasmid, i.e alb for experiment 
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Figure. 3.10. GH3 cells were transiently co-transfected with the following constructs, pGL2-
control, pGL2-basic, wt GnRHR-LUC, mut GnRHR-LUC and 13-galactosidase as described 
earlier. DNA concentrations used for transfections are showed in Table 3.5. Numbers 1, 2, 3 and 
4 represents transfecting with pGL2-control, pGL2-basic, wt GnRHR-LUC and mut GnRHR-
LUC, respectively. Each bar represents the mean ± standard error of one experiment done in 
duplicate. 
5.2.3. Results of transf ections with COS-1 cells 
Table 3.7. Concentrations of DNA used for lipofectin mediated transfection and 13-galactosidase 
and luciferase activity measured in COS- I cells. Abbreviations used in table: cont, pGL2 
positive control; basic, pGL2 negative control; wt, wt GnRHR-LUC; mut, mut GnRHR-LUC; 
13-gal, 13-galactosidase; SF- I, steroidogenic factor- I ; lucif, luciferase; rel. act. , relative activity 
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Concentration ofDNA transfected i ug) 
Activity measured 
Total cont basic wt mut SF-I f3-gal f3-g
alb lucif1 alb rel.act. 
6.25 4.86 1.39 250
 147.9 0.59 1.00 
6.25 4.86 1.39 232
 71.43 0.31 0.53 
6.25 4.86 1.39 315
4 992.8 0.32 0.54 
6.25 4.86 1.39 270
7 1123 0.41 0.70 
6.25 4.86 1.39 0.00
 0.00 0.00 0.00 
6.25 4.86 1.39 0.00
 0.00 0.00 0.00 
6.25 4.86 1.39 0.00
 0.00 0.00 0.00 
6.25 4.86 1.39 0.00
 0.00 0.00 0.00 
6.25 4.86 1.39 258
.5 1.99 0.008 0.01 
6.25 4.86 1.39 371
.9 0.754 0.002 0.003 
6.25 4.86 1.39 2911 
4.42 0.002 0.003 
6.25 4.86 1.39 424
7 6.41 0.002 0.003 
4.86 2.74 1.39 52.25 1.363 0.03 0.05
 
9.0 4.86 2.74 1.39 57.7
4 0.952 0.02 0.03 
9.0 4.86 2.74 1.39 265
.7 4.42 0.02 0.03 
9.0 4.86 2.74 1.39 190.7 
1.92 0.01 0.02 
6.25 4.86 1.39 482 
1.11 0.002 0.003 
6.25 4.86 1.39 459 
1.09 0.002 0.003 
6.25 4.86 1.39 4369 
6.79 0.002 0.003 
6.25 4.86 1.39 3631 
3.26 0.001 0.002 
9.0 4.86 2.74 1.39 41.23 
0.70 0.02 0.03 
9.0 4.86 2.74 1.39 40.7 
0.224 0.006 0.01 
9.0 4.86 2.74 1.39 306.6 
3.34 0.01 0.02 
9.0 4.86 2.74 1.39 303.4 2.
85 0.01 0.02 
a= luciferase activity = iuciferase units I mg protein 
b f.l 1 "d · · OD420/hr/ = ..,-ga actost ase acttvtty = mg protein 
alb= nomalised activity, i.e. luciferase activity per f3-galactosidase ac
tivity 
relative luciferase activity= activity relative to the pGL2-control pl
asmid, i. e alb for experiment 
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Figure. 3.11 . COS-1 cells were transiently co-transfected with the following constructs, pGL2-
control, pGL2-basic, wt GnRHR-LUC, mut GnRHR-LUC, SF-1 and f3-galactosidase cDNA as 
described earlier. DNA concentrations used for transfections are showed in Table 3.5. Numbers 
1, 2, 3, 4, 5 and 6 represents transfecting with pGL2-control, pGL2-basic, wt GnRHR-LUC, wt 
GnRHR-LUC plus SF-I cDNA, mut GnRHR-LUC and mut GnRHR-LUC plus SF-I cDNA, 
respectively. Each bar represents the mean ± standard error of four experiments. 
5.3. Analysis of results of functional assays 
5.3.1. 563 hp of the GnRHR gene 5' to the translation start site is sufficient for promoter 
activity 
To test promoter activity of the 563 bp fragment of the GnRHR gene constructs were 
transfected into aT3- l and GH3 cells. No luciferase activity was produced by the pGL2-basic 
vector. No significant difference in luciferase activity produced by the wt GnRHR-LUC and the 
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mut GnRHR-LUC constructs was detected in any of the cells. Both c
onstructs produced about 
half the luciferase activity produced by the pGL2-control plasmid in 
aT3-l cells (wt GnRHR-
LUC and mut GnRHR-LUC produced 45% and 55%, respectively)
 (Fig. 3.9). In GH3 cells 
constructs produced a similar level of luciferase activity compared to t
he pGL2-control plasmid 
( activity of both constructs relative to the pGL2-control plasmid was 
I 00%) (Fig. 3. 10). These 
results indicated that the 563 bp fragment of the GnRHR gene contain
s strong promoter activity 
in both aT3-l and GH3 cell lines with activity in GH3 cells being hig
her than that produced in 
aT3-l cells (activity of GnRHR constructs relative to the pGL2-cont
rol plasmid was 100% in 
GH3 cells compared to 50% in aT3-l cells). The reason for
 the lower activity of both constructs 
in aT3-l cells relative to GH3 cells may be due to the presence of an
 inhibitor in aT3-l cells, 
binding to a site other than the SF-I site. Alternatively, an enhancer f
actor interacting with the 
promoter at a site other than the SF- I site, present in GH3 cells but 
absent from aT3- l cells, 
may be necessary for the higher levels of GnRH receptor gene express
ion observed in GH3 cells 
relative to aT3- l cells. 
5.3.2. Promoter activity of the 563 hp fragment is tissue-specific 
To test for tissue specificity of the 563 bp fragment constructs w
ere transfected into the 
transformed pituitary cell lines, aT3-l and GH3, as well as into a
n unrelated cell type, a 
transformed kidney cell line, COS-I cells. No significant promoter act
ivity was produced in the 
non-pituitary cell line, COS- I (Fig. 3 .11) whereas high levels of promo
ter activity was observed 
in both aT3-l and GH3 cells. Luciferase activity of the wt GnRHR-LU
C and mut GnRHR-LUC 
constructs was between 140-233 X less than that produced by the 
pGL-2 control vector in 
COS-I cells, whereas luciferase activity of the wt GnRHR-LUC
 and mut GnRHR-LUC 
constructs was 50% and I 00% relative to the pGL2-control plasmid 
in aT3- l and GH3 cells, 
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respectively. These results indicated that the 563 bp fragment of the mouse Gn
RH receptor gene 
is sufficient to activate gene expression in a tissue-specific manner in both aT
3-l and GH3 cells, 
but not in an unrelated cell type (COS-1 cells). 
5.3.3. Tissue-specific promoter activity of the 563 hp fragment of the GnRH
R gene is not 
dependent on SF-1 
To determine the role of SF-1 and the 'GSE' on tissue-specific promoter acti
vity of the 563 bp 
fragment of the GnRHR gene, the wild type and mutant luciferase construct
s were transfected 
into aT3-1 , GH3 and COS-1. aT3-l cells contain endogenous SF-1 , wh
ereas GH3 and COS-1 
cells do not. The results for aT3-l cells showed that the 'GSE' on its own 
is not essential for 
promoter activity as similar promoter activity is produced by the wild type a
nd mutant ( where 
the SF-1 site is mutated) luciferase constructs (Fig. 3.9). Interestingly, GH3 cells, 
which do not 
express endogenous SF-1 protein, produced even higher promoter activity 
than aT3-1 cells, 
when transfected with both the wt and mut GnRHR-LUC constructs, stron
gly supporting the 
finding that SF-1 protein is not essential for high levels of GnRHR promoter 
activity. In COS-I 
cells, co-transfection of the wt GnRHR-LUC construct with SF-1 cDNA cau
sed no significant 
difference in the low promoter activity obtained with the wt GnRHR constru
ct alone, implying 
that the absence of SF-1 alone is not responsible for low basal expression in C
OS-1 cells. 
Taken together, these results showed that the 563 bp fragment of the GnRH r
eceptor gene used 
in this study is sufficient for high basal expression in the pituitary cell lines, aT
3-l and GH3 cells, 
but not in the unrelated cell line, COS-1 cells. Also, it seems that the prese
nce of the 'GSE' 
sequence and SF-1 protein is not crucial for promoter activity as mutations o
f the 'GSE' do not 
81 
significantly alter GnRH receptor gene expression and co-transfection with SF-1 cDNA, in cells 
lacking endogenous SF-1 , does not significantly effect GnRH receptor gene expression. 
The results on co-transfection of aT3-l cells with SF-1 cDNA together with GnRHR-LUC 
constructs are difficult to explain. Since aT3-1 cells contain endogenous SF-1 protein, co-
transfection with SF-1 cDNA would thus be expected to have no effect. It is possible that the 
slight (i.e. 2-fold) increase in promoter activity observed in aT3-l cells on co-transfection with 
SF-1 cDNA may be due to effects unrelated to an increase in SF-1 protein levels. 
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CHAPTER4 
DISCUSSION AND CONCLUSIONS 
Transient transfection studies show that the 563 bp fragment of the GnRH receptor gene, used 
in this study, contains strong promoter activity and that the regulatory elements for tissue-
specific expression of the mouse GnRH receptor gene are present within this region. This region 
of the mouse GnRH receptor gene confers tissue-specific but not gonadotrope specific 
expression, as promoter activity is observed in both aT3- l and GH3 cells, but not in COS-1 
cells. Further studies in other cell lines will have to be done to establish more fully the tissue 
specific expression. These findings are consistent with those of Albarracin et al. (1994) who 
showed that 1.2 kb of the 5' -flanking region of the mouse GnRH receptor gene contains 
regulatory elements for tissue-specific expression. It appears that sequences 5' to -500 bp 
relative to the transcription start site are not necessary for this activity, since we have shown 
that only 500 bp of the 5 ' -flanking region of the mouse GnRH receptor gene ( our constructs 
contained the gene from -500 bp to +63 relative to the transcription start site) are necessary for 
promoter activity and tissue-specific expression. 
The role of SF-1 in GnRH receptor gene regulation was also examined in this study. Analysis of 
of the mouse GnRH receptor gene from -500 bp to +63 bp relative to the transcription start 
site, has revealed the presence of a SF-1-like binding site at +48 bp relative to the -transcription 
start site. Gel mobility shift and DNaseI footprinting assays, using nuclear extracts prepared 
from aT3-1 , aT4 and GTl-7 cells, showed that a factor with SF-1-like binding activity binds 
over the GnRH receptor 'GSE'. A weak footprint was seen over the putative GnRH receptor 
GSE. No other footprints were seen on the fragment from -270 bp to + 108 bp. This could 
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indicate that I) no other major protein-DNA interactions occured in this region, or, 2) in vitro 
conditions of the footprint experiment may not optimise binding of other factors, or may not be 
able to mimic conditions in vivo due to, for example, the role of higher order structure ( a 
particular chromatin structure). Although competition with unlabelled GSE and SF-I 
oligonucleotides in gel mobility shift and DNasel footprinting experiments were performed to 
verify the sequence specificity of the DNA-protein interactions, we cannot as yet conclude that 
the nuclear protein(s) in aT3-I and aT4 cells that bind the SF-I-like site is indeed SF-I. This 
could be verified in future by gel mobility shift experiments with antibodies to SF- I the protein. 
SF-I is a transcription factor that regulates steroid biosynthetic enzyme gene expression in 
gonadal and adrenocortical cells, as well as regulating gonadotropin gene expression (Barnhart 
and Mellon, 1994; Lala et al. 1992; Lynch et al. 1993). These findings imply that SF-I may 
form part of a global pathway regulating reproductive function. The role of SF-I in GnRH 
receptor gene expression was investigated. Transfection experiments were conducted in aT3-I, 
GH3 and COS-I cell lines with constructs containing gene sequences from -500 bp to +63 bp 
relative to the transcription start site of the mouse GnRH receptor gene, with wild type or 
mutated SF-I-like sites. aT3-I and COS-I cells were also co-transfected with the wt or mut 
GnRHR constructs plus SF-I cDNA. The luciferase constructs we have used, containing 563 bp 
of the GnRH receptor gene extended until the ATG translation start site (at +63 bp relative to 
the transcription start site) and therefore included the SF-I-like site (at +48 bp relative to the 
transcription start site). The luciferase construct containing 1.2 kb of 5'-flanking region of the 
GnRH receptor gene prepared by Albarracin et al. (1994) was truncated in the middle of the 
putative SF-I site, so they were not able to determine the effect of the presence of a functional 
SF-I site in GnRH receptor gene expression. The results of this study revealed that luciferase 
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constructs with both the wild type and mutant SF-1-like sites showed similar promoter activity 
in aT3-l and GH3 cells. In COS-1 cells, transfection with the wt or mut GnRHR-LUC 
constructs produced no promoter activity. Co-transfection of the GnRH receptor promoter 
constructs, with either the wild type or mutated SF-1-like sites together with SF-1 cDNA 
showed no significant increase in GnRHR gene expression in COS-1 cells. However, in aT3-1 
cells we observed a 2-3-fold increase in luciferase activity when the GnRHR-LUC constructs 
were co-transfected together with SF-1 cDNA. These results imply that an excess of SF-1 
slightly increases gene expression in aT3-1 cells. It is difficult to explain these results as aT3-1 
cells express endogenous SF-1 protein and co-transfection with SF-1 cDNA would be expected 
to have no effect on promoter activity. 
The results of the wt and mut constructs in aT3-1 cells, which contain endogenous SF-1 
protein, imply that SF-1 binding to the SF-1-like site is not necessary for the high level of 
promoter activity in these cells. If SF-1 was necessary for expression, we would have expected 
to see low expression with the mutated construct. However, the results of our gel shift 
experiments showed that SF-1 protein can bind weakly to the mutated 'GSE' in the GnRHR 
gene. Therefore it is possible that the high level of activity obtained with the mutated 'GSE' 
construct was due to some binding of SF-1 protein. 
However, the results in GH3 and COS-1 cells support the conclusion that SF-1 binding to the 
GSE is not necessary for high levels of GnRHR gene expression. GH3 cells do not contain SF-1 
protein but show higher levels (100% luciferase activity relative to control) of expression of the 
wt and mut constructs than aT3-1 cells (50% luciferase activity relative to control). Co-
transfection of SF-1 cDNA with the wt or mut construct did not significantly increase GnRHR 
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gene expression in COS-I cells. If SF-1 was necessary for promoter activity, we would have 
expected to see low activity in the absence of SF-1 cDNA and high activity for the wt construct 
in the presence of SF-1 cDNA, which was abolished for the mutated construct plus SF-1 
cDNA. However, we do not have direct evidence that the SF-1 protein is expressed by the SF-1 
cDNA in COS-I cells. The lack of activity of the GnRHR promoter in COS-I cells may also not 
be entirely due to the absence of SF-1 protein but also to the absence of other tissue-specific 
factors . No promoter activity was observed when these cells were transfected with the wt or 
mut constructs suggesting that GnRHR gene expression is tissue-specific and not expressed in 
COS-I cells. 
Taken together, these results show that SF-1 alone is not necessary for high levels of expression 
of the GnRHR gene. Similar experiments were done by Duval et al. (1997) who showed that a 
58% reduction in promoter activity was observed in aT3-1 cells, when a 'GSE' or SF-I-like 
site was mutated. The reason for the discrepancy between their results and ours is difficult to 
explain, since the experimental errors in our assays (Fig. 3.9) is low enough to be able to detect 
a 60% reduction in promoter activity. Our findings suggest that the presence of an SF-1 site and 
SF-1 protein is not an absolute requirement for GnRH receptor gene expression. This is in 
agreement with the results of Duval et al. (1997). 
aT3-1 and aT4 cells are both transformed gonadotrope cell lines developed by Windle et al. 
(1990). They showed that aT4 cells do not express GnRHR RNA, while aT3-l cells do. We 
were intrigued by this finding and hoped to use aT4 cells as a vehicle to investigate the role of 
SF-1 in GnRHR gene expression. We showed by gel shifts and Northern blotting that aT4 cells 
express SF-1 RNA and most likely SF-1 protein. This has not been previously demonstrated, to 
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our knowledge. From these findings we can conclude that GnRHR expression is not solely 
dependent on SF-1 expression. 
GTl-7 cells are transformed neuronal cells (Mellon et al 1990). Some reports show that 
GnRHR is expressed in these cells (Krsmanovic et al 1993; Li et al. 1996). However, 
contradictory or unclear report are found in the literature. Thus we thought that, as for aT4 
cells, these cells would be a useful model to shed light on the role of SF-1 in GnRHR 
expression. Gel shifts and Northern blot analysis have revealed that neither SF-1 nor GnRHR 
RNA are expressed in these cells, under our conditions. 
The results obtained in this study showed that a major 4.5 kb GnRH receptor mRNA and a less 
abundant 1.8 kb mRNA is present in aT3-l cells. These findings are consistent with those of 
Albarracin et al. (1994), who also found two species of GnRHR mRNA in aT3-l cells. As 
discussed in the introduction, the heterogeneity of the GnRHR trancripts may result from 
multiple transcription start sites, alternative splicing of the gene or alternative polyadenylation 
signals. Although the presence of multiple transcription start sites may play a role in generating 
multiple mRNA species, the difference in size of the transcripts derived from these start sites 
would not be large enough to account for the almost three kilobase difference in the two major 
mRNA species detected in the mouse. This suggests that other mechanisms may contribute to 
the generation of these multiple transcripts of the GnRH receptor gene. The GnRH receptor 
gene is likely to be regulated in a complex manner. We have shown that it is subject to strict 
tissue-specific regulation, which appears to be independent of SF-1 in the cells we have 
investigated. SF-1 may act in conjunction with another factor(s) . Reports have suggested that 
SF-1 may interact with another factor, DAX-1 , to effect gene regulation. It is possible that SF-1 
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regulates DAX-I gene expression since SF-1 binds upstream of the DAX-I gene (Burris et al. 
1995; Ito et al. 1997; Vilain et al. 1997; Yu et al. 1996). We do not yet know the significance of 
this interaction but it is likely that these two proteins act in conjuction to regulate gene 
expression. 
Our :findings suggest that SF-1 is not necessary for tissue-specific expression of the GnRHR 
gene, but that sequences from -500 bp to +63 hp relative to the transcription start site of the 
GnRHR gene is necessary to confer tissue-specificity. This is supported by the observation that 
SF-1 gene expression is not itself restricted to gonadotropes (Ikeda et al. 1993; Ikeda et al. 
1994; Ingraham et al. 1994). Tissue specificity may be a result of the interaction of multiple 
factors binding to sites in the regulatory region of the GnRH receptor gene, possibly in 
conjunction with SF-1. If so, some of these sites may be absent in our construct. Further studies 
on the regulation of SF-1 itself, and its interaction with other transcription factors will shed light 
on its possible involvement in GnRH receptor gene regulation. 
It is possible that our results in transformed cell lines do not accurately reflect the in vivo 
situation. a.T3-1 cells are transformed precursor gonadotrope cells (Windle et al. 1990) which 
express the a. subunit but not the P subunit of the LH and FSH. Thus they do not exhibit some 
of the functions of fully differentiated gonadotrope cells. Some of the factors necessary for SF-1 
dependent GnRHR expression may be absent from the cell line. In addition, SF- I may require a 
ligand to exert its regulatory role on the GnRHR promoter, and this ligand may be absent in our 
tissue culture system. SF-I may be involved in mediation of another factor(s) involved in 
intracellular signalling, such as the PKC or PK.A system. These possibilities need to be 
investigated. Alternatively, SF-1 may have nothing to do with GnRHR expression. 
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Gel shift and footprint analysis have been used in this study to show that the 'GSE' site on the 
GnRHR binds a protein(s) in vitro which could be SF-1. However, no direct evidence is 
available to show that it is SF-1 , and not another transcription factor which binds to a similar 
binding site. It is known that the SF-1 recognition site is similar to that of some members of the 
steroid receptor superfamily (Barnhart and Mellon, 1994). Also, in vitro binding is not a proof 
of functionality, so the GSE site on the GnRHR promoter may also have nothing to do with 
GnRHR expression. 
The GnRHR 'GSE' occurs at +48 bp relative to the transcription start site, i.e. it is in the 5' 
untranslated region of the mRNA transcript and not 5' to the transcription start site. Some genes 
have transcriptional regulatory elements in the untranslated region but most to date appear in the 
non-transcribed regions. Maybe the real activity of the GnRHR 'GSE' in vivo may be 
translational regulation which also requires the presence of the coding region of GnRHR in the 
transcript. Many reports have been published that elements in the untranslated regions are 
involved in translational regulation (Boado et al. 1996; Manzella and Blackshear, 1990; 
Sonenberg, 1994; Timmer et al. 1993). It would therefore be interesting to see whether the 
'GSW pl~ys ~ rol~ in translational regulation of the GnRH receptor. 
' I • II • : · : I I ~ I f • ' • : ' I ~ • ' T l I ' I i 
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APPENDIX A 
MEDIA 




bacto-yeast extract 5.0g 
NaCl 10.0g 
agar 12.0g 
H20 to one litre 
pH7.0 
bacto-tryptone 10.0g 
bacto-yeast extract 5.0g 
NaCl 10.0g 
H20 to one litre 
pH7.0 
2 x Yeast Tryptone (2 X YT) broth: 
\If broth: 
bacto-tryptone 16.0g 
bacto-yeast extract 10.0g 
NaCl 5.0g 














to one litre 
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APPENDIXB 
BUFFERS AND SOLUTIONS 
Buffers and solutions used for plasmid DNA isolation 
Solution 1: 
IM Tris-Cl (pH 8.0) 2.5 ml 
O.SMEDTA(pH 8.0) 10.0 ml 
20% (w/v) Glucose 5.0 ml 
H20 to 100 ml 
Solution 2: 
IOMNaOH 2.0 ml 
25% (w/v) SDS 4.0ml 
H20 to 100 ml 
Solution 3: 
SM Potassium Acetate 60ml 
glacial acetic acid 11.5 ml 
H20 to 100 ml 
TE buffer: 
IM Tris-Cl (pH 7.5) 1.0 ml 
0.5 M EDTA (pH 8.0) 0.2 ml 
H20 to 100 ml 
Buffers and solutions used for agarose gel electrophoresis 
Tris-acetate buffer (SOX): 
Tris base 
O.SM EDTA (pH 8.0) 





to one litre 
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6X Stop/Loading buffer: 
Glycerol 50.0 ml 
0.5M EDTA (pH 8.0) 20.0 ml 
10% (w/v) SDS 10.0 ml 
Bromophenol Blue 0.1 g 
Xylene Cyanol 0.1 g 
H20 to 100 ml 
Buffers used for preparation of competent cells 
TFBI buff er: 
Potassium Acetate 0.294 g 
RbCh 0.121 g 
CaCh.2H20 0.147 g 
MnCh.4H20 0.990 g 
Glycerol 15 .0 ml 
H20 to 100 ml 
pH 5.8 
TFBil buff er: 
MOPS 0.1045 g 
RbCh 0.5520 g 
CaCh.2H20 0.0610 g 
Glycerol 7.5 ml 
H20 to 50 ml 
pH6.8 
Buffers and solutions used for DNA sequencing 
Tris-borate buff er (5X): 
Tris base 
Boric acid 





to one litre 
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to one litre 
Buffers and solutions used for mutagenesis 
lOX PEl buffer: 





lOX PE2 buff er: 




Solutions used for DNA labelling 
STE buffer: 
IM Tris-Cl (pH 8.0) 















to 100 ml 
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Buffers and solutions used for nuclear extract RreRaration 
PBS: 
NaCl 8.00 g 
KCl 0.20 g 
Na2HP04 1.44 g 
KH2P04 0.24g 
H20 to one litre 
pH7.4 
TBS: 
NaCl 8.0 g 
KCl 0.2 g 
Tris base 3.0 g 
H20 to one litre 
pH7.4 
Buffer A: 
lM HEPES (pH 7.9) 0.5 ml 
lMKCl 0.5 ml 
0.5M EDTA (pH 8.0) 0.01 ml 
0.2MEGTA 0.025 ml 
lMDTT 0.05 ml 
0.2MPMSF 0.125 ml 
H20 to 50 ml 
Buffer C: 
lM HEPES (pH 7.9) 1.0 ml 
5M NaCl 4.0ml 
0.5M EDTA (pH 8.0) 0.1 ml 
0.2MEGTA 0.25 ml 
IMDTT 0.05 ml 
0.2MPMSF 0.25 ml 
H20 to 50 ml 
Buffers and solutions used for RNA isolation and Northern Blot Analysis 
Solution D: 
Guanidinium Thiocyanate 
IM Sodium Citrate (pH 7.0) 
10% (w/v) Sarcosyl 
~-mercaptoethanol 
DEPC-treated H20 
lOX MOPS buffer: 
Morpholinopropanolsulfonic acid 
Sodium Acetate 






20X SSPE buff er: 
NaCl 
NaH2P04.H20 













to one litre 
175.3 g 
88.2 g 




to one litre 
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Buffers and solutions used for cell culture 
Buffer I: 
NaCl 4.10 g 
KCl 0.15 g 
HEPES 2.40 g 
BSA (fatty acid free) 0.50 g 
Glucose 0.75 g 
0.5M EDTA (pH 8.0) 2.0ml 
H20 to 500 ml 
pH 7.4 
Trypsin: 
For COS-1 cells 
EDT A ( disodium salt) 0.20 g 
NaCl 8.00 g 
KCl 0.20 g 
Na2HP04 1.15 g 
KH2P04 0.20 g 
Glucose 0.20 g 
Trypsin 1.25 g 
H20 to 100ml 
pH7.2 
For GTl-7 cells 
EDT A ( di sodium salt) 0.20 g 
NaCl 8.00 g 
KCl 0.20 g 
NaiHP04 1.15 g 
KH2P04 0.20 g 
Glucose 0.20 g 
Trypsin 2.50 g 
H20 to 100 ml 
pH7.2 
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HEPES buff er: 
NaCl 0.8 g 
HEPES 0.5 g 
H20 to 50 ml 
pH 7.10 
lOOx P04: 
Na2HP04 0.50 g 
NaH2P04 0.42 g 
H20 to 50 ml 
pH7.0 
Buffer Z: 
Na2HP04 1.70 g 
NaH2P04.2H20 1.25 g 
KCl 0.15 g 
IM MgCh.6H20 0.2ml 
P-mercaptoethanol 790 µl 
H20 to 200 ml 
pH7.0 
